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RATIONALE AND BACKGROUND: Cardiovascular disease is a major cause of morbidity 
worldwide, being responsible for up to 32% of all deaths in Portugal. Hypertension is 
highly prevalent and one of the major risk factors for cardiovascular disease. Over 42% 
of the Portuguese adults (18-90 years) would have hypertension. Even though the 
benefits of antihypertensive drugs in reducing the risk of major cardiovascular events 
have been extensively demonstrated, the control of hypertension continues to be 
inadequate. The precise reasons for patients not achieving target blood pressure despite 
being treated are not completely clear yet, but one major (and modifiable) reason is the 
fact that patients often do not only fail to take their medication as has been prescribed, 
but also fail to use it for a long uninterrupted period of time. A substantially poorer 
medication adherence rate is observed when analysing newly diagnosed patients, and 
accounting for those who fail to initiate treatment, fail to ever refill, and time after 
discontinue, rather than the more commonplace approach of only observing ongoing 
users. Conventional adherence measures therefore systematically underestimate the 
public health burden of poor medication adherence of newly prescribed medications.  
 
OBJECTIVE: The main objective of this thesis is to determine adherence to 
antihypertensive therapy in newly treated hypertensive patients in primary health care 
units from Lisbon and Tagus Valley Region. 
 
METHODS: This thesis reports data from a large, population-based, retrospective, cohort 
study that assessed adherence to antihypertensive therapy, in all its components, i.e., 
initiation, implementation and discontinuation, in newly diagnosed and treated 
hypertensive patients in primary health care units of Lisbon and Tagus Valley from 
January 1st to March 31st 2011 who used no antihypertensive drugs prior to January 1st 
2011. We’ve also determined primary adherence rate to antihypertensive drugs, 
expressed as the number of claims records divided by the total number of prescriptions 
records. Data were collected from SIARS for each patient during a two-year period after 
the date of the first acquisition. Initiation was determined by the acquisition of a first 
prescription in a pharmacy within a six-month period. Implementation was quantified 
by estimation of Medication Possession Ratio and persistence was determined by the 
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proportion of patients remaining on any antihypertensive drug regardless of switching 
or the use of multiple drugs during follow-up. Persistence was analysed considering a 
maximum allowed treatment gap of 90 days. Reinitiation was also analysed. Initiation 
and persistence were analysed by Kaplan-Meier survival analysis and Cox proportional 
hazard regression was used to estimate hazard ratios for initiation and discontinuation. 
Logistic regression was used to estimate the odds ratio for poor implementation of the 
prescribed AHT therapy. 
 
RESULTS: Overall primary adherence rate was 58.5%, increasing with age. Primary 
adherence rates were higher for men, patients living in the Lisbon Metropolitan Area 
and diagnosed with ICPC-2 code k87. Drugs acting on the Renin-angiotensin system 
had the highest primary adherence rates, increasing for fixed-dose combinations and 
diminishing with the increase of out-of-pocket cost for patients. Of the 10,204 cohort 
members, 493 (4.8%) never acquired any antihypertensive drug and 855 more (8.4%) 
initiated hypertension treatment with a considerable delay (six-months or longer) after 
the first prescription, being classified as ‘non-users’. After adjustment for all the 
potential predictors of initiation, women, and patients aged 45-64 years, who received 
an initial prescription of with two or more drugs had higher initiation rates. Among 
patients with a first dispensing (n=8,856), 638 (7.2%) patients discontinued 
antihypertensive therapy after acquiring just the first prescription and 519 more (5.9%) 
completely discontinued treatment during the first year, making a total of 1,157 (13.1%) 
patients who were no longer on treatment at the end of the first year. During the second 
year, 904 (10.2%) more discontinued antihypertensive therapy. However, in spite of 
6,157 patients being still on treatment two years after the initiation of hypertension 
treatment, only 539 (8.8%) of them were classified as continuous users, i.e. had no 
treatment gap or grace period of 90 days or longer, meaning that the remaining 5,618 
(91.2%) were using antihypertensive therapy in an ‘on and off’ basis, discontinuing and 
reinitiating it over time. The risk of complete discontinuation was higher for younger 
patients, treated with monotherapy and followed by a single physician. Analysing the 
implementation of hypertension treatment in the two-year observation period, among 
patients with a first dispensing only 456 (5.1%) had in their possession antihypertensive 
drugs for 80% or more days, regardless the occurrence of lapses in implementation, i.e. 
treatment gap or grace periods of 90 days or longer, which occurred in 233 (51.1%) of 
this patients with a high level of implementation.  Younger patients and with a higher 
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buying power had a higher risk for poor implementation. However, and in spite of 
increasing persistence, the use of more drugs during the follow-up decreased the 
medication possession ratio for this patients. 
 
CONCLUSION: The results of this thesis confirm previous observations that in clinical 
practice hypertension treatment is frequently abandoned and poorly implemented over 
time. Our results demonstrated that almost one out of five (19.5%) patients either never 
initiated treatment, did it with a considerable delay (after six months or more after their 
first prescription) or completely discontinued it just after acquiring their first 
antihypertensive drug, being the risk for discontinuation most pronounced during the 
first year. Low adherence rates to antihypertensive therapy, in all its components, are an 
especially alarming finding, since this condition contributes greatly to the burden of 
mortality and morbidity from cardiovascular disease in Portugal. Until this thesis, little 
was known in Portugal about adherence to antihypertensive therapy, especially at a 
population level. With this thesis we demonstrated not just the patterns of adherence to 
antihypertensive therapy but also some possible risk factors for non-adherence.  
 
KEY-WORDS: Adherence to antihypertensive therapy; primary adherence; initiation, 
implementation and discontinuation. 
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SCOPE OF THIS THESIS 
 
Hypertension is an important risk factor for the development of cardiovascular (CV) 
morbidity and mortality1-7; about half of all cardiovascular disease (CVD) combining 
mortality and morbidity, can be attributable to high blood pressure (BP)1-3.  
 
Fortunately, hypertension is also widely considered as one of the most preventable 
causes of CVD because of the availability of effective antihypertensive (AHT) drugs, 
whose benefits in reducing BP have been extensively demonstrated over the last 
decades5-14.  
 
All classes of AHT drugs which are now considered to be first line treatment for 
hypertension have shown a comparable reduction in CV complications6-7,14. Lowering 
systolic BP by 10 mmHg or diastolic BP by 5 mmHg reduces CV events (fatal and non-
fatal) by approximately 25% and cerebrovascular events by 30%14. Compared to no 
treatment, AHT drugs have also demonstrated the potential to reduce the risk of CV 
mortality by 19% and the risk of all CV mortality by 10%15.   
 
However, the literature indicates that up to two thirds of patients with hypertension are 
not successfully treated4,6,12. In Portugal, the PHYSA (Portuguese Hypertension and 
Salt) Study shown that 23.4% of the Portuguese with hypertension are unaware of their 
condition, and overall, among hypertensive patients, only 42.5% reach a controlled BP 
below 140/90 mmHg16. 
 
It is therefore paradoxical that despite the availability of effective AHT drugs and the 
progress that has been made in the treatment of hypertension, the number of people 
whose BP is controlled is disappointingly low12,17. 
 
MANAGEMENT OF HYPERTENSION 
 
The management of hypertension is based on two major approaches: a modification of 
lifestyle and the lifelong prescription of AHT drugs4-7, being the latter the cornerstone 
of the medical management of hypertension5-7,18. Thus, the use of AHT drugs for long 
uninterrupted periods of time is important because incorrect use will lead to a less 
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effective treatment in daily practice than observed in randomized clinical trials (RCT)18-
22. 
 
Therefore, patients who start hypertension treatment should be prepared to take AHT 
drugs for a lifelong period. Yet, patients often do not only fail to take their drugs as has 
been prescribed by their physicians, which is commonly designated by non-adherence, 
but also fail to use them for a long uninterrupted period of time, e.g. non-
persistence8,13,18,23-24, which will ultimately lead to a less effective treatment.  
 
ADHERENCE AND PERSISTENCE 
 
Although adherence and persistence are conceptually linked together, and even 
interchanged in medical literature, they refer to a different problem. Adherence to 
medications is defined as the process by which patients take their medications as 
prescribed, including three components: initiation, implementation and 
discontinuation25. It is usually expressed as a percentage or fraction of doses taken as 
scheduled23,26. In this context, non-adherence refers to problems such as missing doses - 
intentionally or not -, or short periods of so called ‘drug holidays’, periods during which 
patients consciously do not take their medications, but restart thereafter. This means that 
in case of non-adherence, a patient does have the intention to use treatment for longer 
periods, but not always as prescribed. The long-term consequence is that the full benefit 
of treatment cannot be obtained making the patient sub-optimally protected18,25,27.  
 
The term persistence is used to characterize patients that continue their treatment for a 
specified period of time. In case of non-persistence, patients completely discontinue the 
use of a certain drug or treatment regimen, in contrast to non-adherence where only 
some doses are omitted. Therefore, non-persistence constitutes an even greater barrier to 
attain treatment goals25,28.  
 
In this context, non-adherence and/or non-persistence to AHT therapy represent an 
important component of preventable CV morbidity and mortality8-9,11-13, since their 




Non-adherence to and non-persistence with prescribed medications is a widely prevalent 
problem; analysis of the electronically monitored dosing histories of approximately 
17,000 RCT participants revealed that, during a year of observed treatment, almost 40% 
of participants had discontinued taking the prescribed drug (including 4% who never 
initiated their treatment), and in addition, 15% of participants were occasionally 
omitting some of their prescribed doses29.  
 
USE OF PRESCRIPTION AND DISPENSING/CLAIMS DATABASES FOR QUANTIFICATION OF 
ADHERENCE TO MEDICATIONS 
 
An appropriate quantification of adherence to medications is fundamental in everyday 
clinical practice. There are many different methods for assessing adherence to 
medications, which Osterberg and Blaschke23 categorized as either direct or indirect.  
 
With the development of several prescription databases in the 1980s, it became possible 
to observe large numbers of patients in real world clinical settings. This also provided 
researchers an easy and inexpensive opportunity to obtain information on patterns of 
use of multiple drug classes, including AHT drugs30-33.  
 
Rates of pharmacy refills, extracted from pharmacy dispensing/claims databases, can be 
used as a surrogate for adherence to medications – indirect method23. First, they reflect 
patients’ decision to continue with treatment and secondly, patients’ effort to obtain the 
prescribed medication as the first step towards taking it34. Rates of pharmacy refills by 
assessing whether patients fill (acquire) their prescribed medications over specified time 
intervals, allow the evaluation of the medication-acquisition behaviours30,34. 
 
Little is known in Portugal about adherence and persistence to AHT therapy, especially 
at a population level. To our best knowledge this is the first study in the country to 
quantify adherence with AHT therapy in its three components and including all AHT 
drug classes at a population level, using prescription and dispensing/ claims databases. 
Previous studies35-41 were focused on local populations and quantified adherence to 
AHT therapy using questionnaires and/or interviews of patients. With the exception of 
Costa et al study41, all studies evaluated only the component of implementation of AHT 
therapy. A recent study42 conducted in the Alentejo Health Region also evaluated AHT 
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therapy using prescription and dispensing/claims databases, though it was focused on 
just one AHT drug class. 
 
OUTLINE OF THIS THESIS 
 
The main objective of this thesis is to determine adherence to AHT therapy in newly 
treated hypertensive patients in Primary Health Care (PHC) units from Lisbon and 
Tagus Valley Health Region, in its three components – initiation, implementation and 
discontinuation. Additionally, we aim to identify risk factors for non-adherence and 
non-persistence.   
 
This thesis is divided into seven chapters. In chapter one to three, we present the 
theoretical framework on adherence to medications, focusing on hypertension. Chapter 
one specifically focuses on hypertension prevalence, definition and classification, and 
also treatment recommendations. In this chapter, we also describe the relationship 
between BP control and adherence to medications, building a bridge for chapter two, 
where we provide a conceptual framework on adherence, in its various definitions and 
issues. We also describe risk factors for non-adherence, using the five categories 
defined by the World Health Organization (WHO) as a reference.  
 
In chapter three, we describe different methods for quantification of adherence to 
medications, focusing on rates of pharmacy refill.      
 
In chapter four we describe the objectives of this thesis and in chapter five we describe 
in detail, the methodological issues of the study design, including a previous description 
of the local context where the study was conducted. Special attention was dedicated to 
exposure definitions and measures used in this thesis for determining the several rates of 
adherence. 
 
In chapter six we present the main findings of our study, accordingly to the different 
components of adherence – initiation, implementation and discontinuation.  
 
Finally, in the discussion chapter – chapter seven – the results of this thesis are 
compared to the published literature on adherence to AHT therapy and put in 
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perspective and the novelty of our findings, but also the study limitations are 
emphasised. 
 
To comply with NOVA Medical School recommendations, at the end of this thesis 
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11 HYPERTENSION 
1.1. PREVALENCE OF CARDIOVASCULAR DISEASE: FOCUS ON HYPERTENSION 
 
CVD is the main cause of premature death in industrialised countries1-3,43 and is also a 
major cause of morbidity worldwide, as well in Portugal16,44 where it is responsible for 
up to 32% of all deaths10.  
 
The high prevalence of hypertension worldwide has played a major contribution to the 
global burden of disease associated to CVD. Almost ten years ago, Kearney and 
colleagues1 analysis indicated that more than a quarter of the world’s adult population 
had hypertension in 2000, and that this proportion would increase to 29% by 2025 – less 
than ten years from now. Overall, the prevalence of hypertension appears to be around 
30-45% of the European population, increasing with age6. 
 
For the last 30 years, Portugal has been among the countries with the highest levels of 
mean BP45. It has been estimated that overall, over 42% of the Portuguese adult 
population aged 18 to 90 years, would have hypertension16,44. In 2008, the prevalence of 
hypertension (or the use of AHT drugs as a proxy for hypertension) in adults aged ≥25 
years was estimated at 41.9%45.  
 
 
1.2. HYPERTENSION AND CARDIOVASCULAR RISK 
 
Hypertension has been identified as the leading risk factor for mortality1-3, and is ranked 
third as a cause of disability-adjusted life-years3. Its importance derives not only 
because of its high frequency – it is in fact, the most common chronic disease in 
developed countries - but also because it is a major modifiable/reversible risk factor for 
CV and kidney disease1,4-6,12-13.  
 
A CV risk factor corresponds to a biological or behavioural characteristic of an 
individual, which is, independently related to the subsequent development of CVD 
and/or CV event, increasing the probability of their occurrence. Any major risk factor, 
such as hypertension, if left untreated for many years, has the potential to produce CVD. 
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Hypertension was perhaps the first well-established CV risk factor. Regardless of the 
underlying cause of high BP, hypertension directly contributes to CVD risk and it 
predicts CVD46. From tensional values of 115/75 mmHg, CV risk doubles for each 20 
mmHg increase in systolic BP and 10 mmHg increase in  diastolic BP49. 
 
In addition, hypertension contributes to the prevalence of other CV risk factors, such as 
insulin resistance, lipid abnormalities, changes in renal function, endocrine 
abnormalities, obesity, left ventricular hypertrophy, diastolic dysfunction, and 
abnormalities in vascular structure and elasticity50. When concomitantly present, high 
BP and other CV risk factors may potentiate each other, leading to a total CV riski that 
is greater than the sum of its individual components6.  
 
Thus, since only a small fraction of the hypertensive population has an elevation of BP 
alone, with the majority exhibiting additional CV risk factors, the 2007 and the more 
recent 2013 European Society of Hypertension / European Society of Cardiology 
(ESH/ESC) guidelines for the management of arterial hypertension6, as well the 
Portuguese Directorate-General of Health Clinical (DGS) Standard10 emphasize that 
management of hypertension should be related to quantification of total CV risk.  
 
 
1.3. DEFINITION AND CLASSIFICATION OF HYPERTENSION 
 
As mentioned, the association between lack of BP control and CV risk and premature 
death has been extensively demonstrated1,6,10,43,51. It is a continuous, consistent and 
independent of other risk factors relationship – the higher the BP, the greater the chance 
of stroke, ischemic heart failure, congestive heart disease failure, and renal failure4-6 and 
the shortening of life expectancy up to 5 years52.  
                                                          
i Total CVD risk is defined as the probability of an individual’s experiencing a CVD event (e.g. 
heart failure, myocardial infarction or stroke) over a given period of time, for example 10 years. 
Total CVD risk depends on the individual’s particular risk factor profile, sex and age; it will be 
higher for older men with several risk factors than for younger women with few risk factors. 
The total risk of developing CVD is determined by the combined effect of CV risk factors - an 
individual with several mildly raised risk factors may be at a higher total risk than someone with 




The continuous relationship between BP and CV and renal events makes the distinction 
between normotension and hypertension difficult when based on cut-off BP values6. In 
practice, however, cut-off BP values are universally used, both to simplify the 
diagnostic approach and to facilitate the decision about treatment6.  
 
Hypertension is defined as values ≥140 mmHg systolic BP and/or ≥90 mmHg diastolic 
BP, based on the evidence from RCT that in patients with these BP values treatment-
induced BP reductions are beneficial5-6,10. BP levels definition and classification 
accordingly are shown in Table 1.  
 
Table 1: Definitions and classification of office blood pressure levels 




Grade 1 hypertension 
Grade 2 hypertension 
Grade 3 hypertension 






















Table adapted from Mancia, et al6 
 
 
1.4. HYPERTENSION TREATMENT  
 
Not only the association between lack of BP control and CV risk has been extensively 
demonstrated; the benefits of AHT therapy in reducing the risk of major CV events 
have also been5-14. Lowering BP is associated with significant decreases in the incidence 
of stroke, ischemic heart failure, congestive heart disease failure, and renal failure, 
irrespective of age, gender, type of AHT used, or severity of hypertension5-7,13-15,49.  
 
Numerous large-scale clinical trials, such as the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT)53 and the Hypertension Optimal 
Treatment (HOT) trial54, have demonstrated the benefits of BP control to reduce CV 
mortality and morbidity in patients with hypertension.  
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Hypertension treatment is based on two major approaches: lifestyle changes and the 
lifelong prescription of AHT drugs4-7. In the short term, it aims to reduce and control BP 
to below 140/90 mmHg if AHT drugs are tolerated and not contraindicated. In the long-
term, the goal of AHT therapy involves countering the progression of the disease and its 
impact on target organs and therefore reducing CV morbidity and mortality as a result 
of hypertension48. 
 
Appropriate lifestyle changes are fundamental for the prevention of hypertension6. It has 
been also widely demonstrated that CVD is strongly associated to lifestyle, especially 
the use of tobacco, unhealthy diet habits, physical inactivity, and psychosocial stress55.  
 
The World Health Organization (WHO) has stated that over ¾ of all CVD mortality 
may be prevented with adequate changes in lifestyle55. Lifestyle changes are also 
important for hypertension treatment: BP-lowering effects of targeted lifestyle changes 
can be equivalent to drug monotherapy. However, such changes should never delay the 
initiation of drug therapy in patients at a high level of risk6-7.  
 
The recommended lifestyle changes that have been shown to be capable of reducing BP 
are: (1) salt restriction, (2) moderation of alcohol consumption, (3) high consumption of 
vegetables and fruits and low-fat and other types of diet, (4) weight reduction and 
maintenance and (5) regular physical exercise. In addition, insistence on cessation of 
smoking is mandatory in order to improve CV risk, and because cigarette smoking has 
an acute pressor effect that may raise daytime ambulatory BP6.  
 
Although counselling about lifestyle changes plays a role, lifelong prescription of AHT 
drugs remains the cornerstone of the medical management of hypertension5-7,18. CV 
drugs (such as statins, AHT, and antithrombotic agents) remain the most common 
medical interventions worldwide for both primary and secondary prevention of CVD, 
through modification of intermediate determinants of CVD56, such as hypertension. 
 
The 2013 ESH/ESC Guidelines6 state that diuretics (including thiazides, chlorthalidone 
and indapamide), beta-blockers (BBs), calcium channel blockers (CCBs), angiotensin 
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are all 
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suitable for the initiation and implementation of hypertension treatment, either as 
monotherapy or in some combinations.  
 
In Portugal, a study performed in the Primary Health Care (PHC) setting, the VALSIM 
(Epidemiological Study of the Prevalence of the Metabolic Syndrome in the Portuguese 
Population) Study, involving 719 general practitioners (GP) and representative of all 
regions of the Country identified diuretics (47.4%), ARBs (43%) and ACEIs (39.2%) as 
the most frequently used AHT drugs for hypertension treatment of the population57. 
 
The previous ESH/ESC Guidelines, back in 2007, underlined that, no matter which drug 
is employed, monotherapy can effectively reduce BP in only a limited number of 
hypertensive patients and that most patients require the combination of at least two 
drugs to achieve BP control5. The VALSIM Study also found that the proportion of 
hypertensive patients under monotherapy was still very high, implicating that increasing 
the use of combination AHT therapy would probably improve BP control in the 
population57. Also the PHYSA study found that among patients with hypertension 
controlled, 39.2% were on monotherapy and 56.4% were on combination therapy57, 
which corroborates that the use of combination AHT therapy improves BP control. 
 
Thus, the issue is not whether combination therapy is useful, but whether it should 
always be preceded by an attempt to use monotherapy, or whether - and when - 
combination therapy may be the initial approach6.  The 2013 ESH/ESC Guidelines6 and 
the DGS clinical standard10, therefore favors the use of combinations of two AHT drugs 
at fixed doses in a single tablet.  
 
Additionally, DGS recommends the following principles in AHT therapy: (1) use of 
generic drugs whenever appropriate and cost-effective; (2) use, where possible, of QD 
(one a day) dosing regimen; (3) if the patient is properly controlled with different 
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1.5. ADHERENCE TO MEDICATIONS AS A BARRIER TO BLOOD PRESSURE CONTROL  
 
Despite the excellent array of effective, well-tolerated drugs used in hypertension 
treatment, its control continues to be inadequate6,12-13,17. Reports suggest that up to two 
thirds of patients with hypertension are not successfully treated, that is, achieve BP 
control4,6,12. In Portugal, the PHYSA study16 found that among hypertensive patients, 
76.6% are aware of their high BP and 74.9% are treated; among treated patients, 55.7% 
have their BP controlled and in the overall hypertensive population the rate of control is 
42.5%, which represents a 3.8 times higher control than it was found in an earlier study 
also in the Portuguese population44. Still, these figures show that there is a large place 
for improvement and hypertension remains a silent and undertreated CV risk factor49.  
 
The precise reasons for patients not achieving target BP despite being treated are not 
completely clear yet. Still, three main causes of the low rate of BP control have been 
identified: (1) physician inertiaii (2) patient low adherence to treatment, and (3) 
deficiencies of healthcare systems in their approach to chronic diseases6. In this context, 
low adherence to treatment is perhaps the most important cause of the low rate of BP 
control8,13,23-24. 
 
A recent systematic review and meta-analysis of epidemiological studies estimated that 
9% of all CV events in Europe could be attributed to non-adherence to CV drugs 
alone56. In the Heart and Soul study58 which examined the impact of self-reported 
adherence, the authors found CV events to be almost twice as high in non-adherent 
participants and remained independently predictive of adverse CV events after adjusting 
for baseline disease severity and other known risk factors. Additionally, discontinuation, 
e.g. non-persistence with AHT therapy in primary prevention increases the risk of acute 
myocardial infarction and stroke59.  
 
                                                          
ii Lack of therapeutic action when the patient’s BP is uncontrolled. It’s generated by several 
factors, such as: doubts about the risk represented by high BP, particularly in the elderly, fear of 
a reduction in vital organ perfusion when BP is reduced and concern about side effects. Several 
physicians also maintain a skeptical attitude towards guidelines because of their multiplicity and 




Many different studies have demonstrated the relationship between adherence to AHT 
therapy and BP control and CV risk, as follows:  
i. A meta-analysis by DiMatteo et al61 reported that patients who adhered to AHT 
therapy were 3.44 times more likely to achieve good BP control than those who 
were non-adherent; 
ii. Bramley et al24 reported that highly adherence patients were 45% more likely to 
achieve BP control than patients with medium or low levels of adherence; 
iii. Corrao et al62 found that high adherence to AHT therapy was associated with 
22% decreased risk of CV events compared with lower adherence. The authors 
also found that persistent patients had a 37% reduction of coronary and 
cerebrovascular risk compared to discontinuers; 
iv. Mazzaglia et al63 found that high adherence to AHT therapy was associated with 
a 38% decreased risk of CV events compared with lower adherence; 
v. Dragomir et al64 found that low adherence was associated with an increased risk 
of coronary and cerebrovascular disease as well as chronic heart failure by 7%, 
13% and 42%, respectively, and an increased rate of hospitalization of 17%. 
This increased risk for vascular events was also associated with substantial costs 
(35% more compared to the costs if patients have been high adherent); 
vi. Pittman et al65 also found that non-adherence to be associated with greater 
healthcare utilization as demonstrated by CV-related hospitalizations (OR=1.33) 
and emergency department visits (OR=1.45); 
 
All this different studies demonstrate that in the longer term, the inadequate control of 
BP that culminates from non-adherence to CV drugs means that patients remain at 
significant risk for costly micro- and macro vascular complications that can result in 
premature mortality18. 
 
That’s why hypertension guidelines4-7,10 recognize that “…the most effective therapy 
prescribed by the most careful clinician will control hypertension only if the patient is 
motivated to take the prescribed medication and to establish and maintain a health-
promoting lifestyle”4. This statement clearly emphasizes the importance of supporting 
adherence to and persistence with treatment for patients to gain the maximal benefits of 
their long-term therapy66.  
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Therefore, treatment, control and prevention of the consequences of hypertension, 
depend on adherence to interventions as much as on those interventions’ efficacy and 
tolerability11,67-68. Adherence to AHT therapy may be the link between disease 
management and attainment of the desired therapeutic result29,69 since high-adherent 
patients have a lower risk of major CV events, hospital admissions and global health 
care costs20,62-65,69. 
 
Non-adherence and/or non-persistence are an important component of preventable CV 
morbidity and mortality8-9,11-12, since the consequences of poor adherence and 
persistence with AHT therapy are the same as those for hypertension itself27.  
 
Although this association between medication non-adherence and adverse outcomes has 
been demonstrated in many observational studies, some concern has been raised that 
this association may be, at least in part, related to a ‘healthy adherer’ effect70-71. The 
healthy adherer effect implies that the lower risk of adverse outcomes associated with 
adherence may be a surrogate marker for overall healthy behaviour56. This is supported 
by post hoc analyses of RCT in which even adherence to placebo is associated with 
better outcomes than for patients who are non-adherent to active treatment, i.e. 
participants in RCT who do not follow medications regimens or placebo regimens have 
a poorer prognosis than subjects in the respective groups who do23,60. It appears that 
patients who take their medication regularly are also more likely to perform other 
healthy behaviours, such as eating properly and exercising regularly56,71, which is not 
measured directly in prospective or retrospective studies. 
 
However, there is also evidence against the healthy adherer effect being a major factor 
in observed associations between medication adherence and outcomes. Based on the 
differential class effects of adherence to medication on long-term survival, it has been 
suggested that adherence related benefits are mostly mediated by drug effects rather 
than by healthy adherer behaviours64. Although the debate will continue, the 
medications under study have often been demonstrated in RCT to be efficacious, and 
therefore, the importance of taking these medications as prescribed should be 
reinforced.  
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2.1. ADHERENCE TO MEDICATIONS: PREVALENCE AND CONSEQUENCES 
 
As expressed in the previous chapter, adherence to prescribed medications (or 
medication adherence) is crucial for therapeutic success, because even the most 
effective and rational pharmacological/medical interventions can be ineffective by 
suboptimal adherence (e.g. partial or complete non-adherence) to them72. Suboptimal or 
partial adherence has been highlighted as a significant obstacle in achieving better 
patient outcomes23,73 by reducing the effectiveness of prescribed medications. That 
translates not just in to a missed opportunity for the treatment’s effect, but also in 
increased healthcare costs74, since the commonly recurring patterns of non-adherence 
create a catalog of therapeutic errors (e.g. failed treatment, inappropriate drug 
escalation, hazardous rebound or recurrent first-dose effects, and even misdiagnosis), all 
of them carrying economic costs72.  
 
Though for many chronic diseases, such as hypertension, pharmacological options are 
available and, in fact, effective as demonstrated in RCT, patients often do not only fail 
to take their medication as has been prescribed by their physician - non-adherence - but 
also fail to use it for a long uninterrupted period of time - non-persistence23. Population-
based studies using pharmacy refill rates have demonstrated that patients typically 
obtain less medication than they have been prescribed30,42,75. 
 
Full recognition of partial/suboptimal adherence or non-adherence to prescribed 
medications is based on discrepancies between the patient’s dosing history and the 
prescribed dosing regimen29. Thus, non-adherence as well as non-persistence constitutes 
major barriers to controlling chronic diseases leading to an increased morbidity and 
mortality67,72, since as Osterberg and Blaschke23 stated “(…) it is clear that the full 
benefit of the many effective medications that are available will be achieved only if 
patients follow prescribed treatment regimens reasonably closely”. 
 
As the burden of disease in the population continues to shift toward chronic diseases - it 
has been estimated that the global economic impact of chronic diseases will continue to 
grow by 2020, at which it will correspond to 65% of healthcare costs worldwide -, the 
problems created by patient’s non-adherence to long-term therapies gain in 
importance50,67,72.   
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Due to its high prevalence, the costs specifically related to hypertension, are substantial. 
The financial impact of hypertension stems not only from the treatment of high BP, but 
also from the costs of managing the chronic diseases linked with this medical 
condition64.  
 
Adherence to medications plays in this context, a key role in the clinical management 
process76. The issue has a global relevance particularly in wealthier nations, where 
access and use of healthcare systems are high, and further increasing the effectiveness 
of a medication could rely largely on improving adherence levels77.  
 
As mentioned in the Introduction of this thesis, non-adherence to prescribed 
medications is a widely prevalent problem; it has been estimated that during the first 
year of observed treatment, almost 40% of participants discontinue taking the prescribed 
drug (including 4% who never initiated their treatment), and in addition, 15% of 
participants occasionally omit some of their prescribed doses29. A WHO previous 
report11 on adherence to long-term therapies has estimated that one in every two patients 
in developed nations do not adequately adhere to long-term therapies. More recently, a 
systematic review and meta-analysis of epidemiological studies conducted by 
Chowdhury et al56 demonstrated that the proportion of patients with good adherence to 
CV drugs is approximately 57%. 
 
Considering these figures, it has been suggested that increasing the effectiveness of 
methods for improving adherence may have a far greater positive impact on human 
health and its economics than any single improvement in medical treatment78. For this 
reason, adherence to medications has been called the “next frontier in quality 
improvement” and is an important part of CV outcomes research79 since poor adherence 
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2.2. MEDICATION ADHERENCE DEFINITION 
 
Over time, a variety of terms have been used to define different aspects of the act of 
seeking medical attention, acquiring prescribed medications and taking those prescribed 
medications appropriately. These terms include ‘compliance’, ‘concordance’, 
‘adherence’ and ‘persistence’. Although often used interchangeably, these terms imply 
different views about the relationship between patients and healthcare 
professionals25,29,72.  
 
The term ‘compliance’ represents the traditional approach to prescribed medications and 
taking them. It was initially defined as “the extent to which a person’s behaviour 
coincides with the clinical perspective”81. Introduced in 1975 as an official Medical 
Subject Heading (MeSH) in the United States National Library of Medicine, it has a 
widely perceived, somewhat negative connotation that patients are subservient to 
prescribers25. In fact, during early research on this topic, the role of patient’s views on 
medication adherence was perfectly neglected. Within this medical dominance 
perspective, the patient should passively obey to the prescriber’s instructions; any 
deviation should be considered the patient’s only responsibility and therefore, the 
patient should be blamed for it17,25,60,67,82.  
 
The term ‘compliance’ has been increasingly replaced by ‘adherence’, as the latter has 
been thought to evoke more the idea of cooperation between prescriber and patient. To 
the WHO, medication adherence can be defined as “the extent to which a patient’s 
behaviour, with respect to taking medication, corresponds with agreed 
recommendations from a healthcare provider”11.  
 
The shift from ‘compliance’ to ‘adherence’ reflects a fundamental change in 
understanding relationships between patients and healthcare professionals25,67. 
 
It was in the light of this shift that the term ‘concordance’ was proposed, originally to 
describe the patient–prescriber relationship. The ‘concordance’ construct recognized the 
need for patients and healthcare providers to cooperate in the definition of a mutually 
agreed treatment programme, acknowledging that patients and providers may have 
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divergent views. However, this term is sometimes incorrectly used as a synonym for 
‘compliance’25. 
 
Another term, ‘persistence’, or continuation, is used to characterize patients that 
continue on treatment for a defined period of time. In case of non-persistence, patients 
completely discontinue the use of a certain drug or treatment regimen, in contrast to 
non-adherence where only some doses are omitted25,83. Although adherence and 
persistence are both components of appropriate medication use, they have differing 
clinical implications84. The effects of non-adherence may be less overt; observed 
changes in BP may be less dramatic than those seen with non-persistence86, therefore, 
non-persistence constitutes an even greater barrier to attain treatment goals. 
 
Figure 1 shows different patterns of execution/implementation and discontinuation of 
AHT therapy.  
 
 
Figure 1. Differences between adherence and persistence (adapted from Lowy87) 
 
In light of all this, although many studies have examined adherence to medications over 
many years, the absence of a common taxonomy and the lack of reliable measurements 
of ambulatory patients’ exposure to prescribed medications have resulted in much 
confusion, with adherence rates ranging from 15% to as high as 97%62,68,87-88.  
 
Also, a number of population-based studies have demonstrated high discontinuation 
rates varying from 35% to 84%19,28,90-95. Cramer et al96 in their review demonstrated that 
is a statistically significant trend towards decreased persistence with time. Other studies 
show that non-persistence continues to reduce the number of patients still engaged with 
AHT drug dosing regimens out to five years or more after the onset of treatment, by 
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which time only 10% to 15% of the originally treated patients are still engaged with the 
regimen97.  
 
Thus, the wide range of adherence and persistence (or discontinuation) rates in 
published studies is presumably a reflection not only of the range of methodologies and 
AHT drugs that have been used but also of the number and complexity of reasons for 
poor medication-taking behaviour18. 
 
In 2012, a European consensus on terminology was proposed by the European Union-
sponsored ‘Ascertaining Barriers for Compliance’ Project (ABC Project)77, in which 
adherence to medications is defined as “the process by which patients take their 
medications as prescribed”; medication adherence consists of three elements: initiation, 
implementation and discontinuation. “The most fundamental point in this novel 
approach is that adherence is not a therapeutic parameter that can be described by a 
single number, as usually reported in the literature. Adherence is essentially a dynamic 
process, with sometimes slow-to-change effects on drug actions of variable exposure to 
prescribed drugs”25. Recognition of the dynamic nature of medication adherence is 
important when considering ways in which poor medication-taking behaviour could be 
improved18. 
 
The process starts with initiation of the treatment, which occurs when the patient takes 
the first dose of a prescribed medication, after its acquisition from a pharmacy25,30. The 
intervening part of the process is implementation of the dosing regimen, defined as “the 
extent to which a patient’s actual dosing corresponds to the prescribed dosing regimen, 
from initiation until the last dose is taken”. The process ends (discontinuation) when the 
patient stops taking the prescribed medication25. Persistence represents the accumulation 
or length of time from initiation to discontinuation of therapy18,25.  
 
So, non-adherence to medications can occur in the following situations or combinations 
thereof: late or non-initiation of the prescribed treatment, sub-optimal implementation 
of the dosing regimen and/or early discontinuation of treatment25.  
 
Non-adherence can also be looked at as being intentional or non-intentional. Intentional 
non-adherence is an active process whereby the patient chooses to deviate from the 
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healthcare provider’s recommendations. This may be a rational decision process in 
which the individual weighs the risks and benefits of treatment against any adverse 
effects; the patient consciously self-adjust its regimen, or prematurely terminate 
medication use, because of side-effects and toxicity, personal beliefs or convenience. 
Unintentional non-adherence is a passive process in which the patient may 
unintentionally fail to fill the prescription, forget a dose or may take it incorrectly 
because misunderstanding or forgetfulness of healthcare provider’s instructions11,84,98-
100.  
 
As a consequence, intentional versus non-intentional non-adherence patients may 
struggle with different adherence determinants, requiring different interventions11. 
 
2.2.1. First element of the adherence process: initiation  
 
Initiation is often reported as the time from the first prescription until first dose is taken. 
It is thus a time-to-event variable with a well-defined time origin (prescription) and an 
end-point which is the first dose taken, usually designated as index date25. 
 
In the literature, the terms ‘primary adherence’101-102, ‘first-fill adherence’103 and ‘initial 
medication adherence’104 are also used. Primary adherence or initial medication 
adherence refers to a new prescribed medication being dispensed at a pharmacy 
(acquired or sold) within a defined number of days after it was prescribed101-105. It is a 
discrete event that assesses whether or not the patient received the first prescription101-
105. 
 
By opposition, primary non-adherence can be defined as a failure to have a new 
prescription dispensed (patient did not acquire the first prescription) within a defined 
number of days after the medication was prescribes101,106-107. 
 
Though it’s a recent concept, a number of population-based studies have demonstrated 
high primary non-adherence rates varying from 4.7% to 33%41,64,101,108-113. 
 
In the literature, the term ‘primary adherence’ is often described as the acquisition of 
prescribed medications in opposition to ‘secondary adherence’, the actual medicine-
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taking behaviour once the medications have been purchased41. In the conceptual model 
proposed by Raebel et al101, ‘secondary adherence’ is an ongoing process that measures 
whether or not the patient received dispensings or refills as prescribed during a defined 
observation period.  
 
Shrank et al107 found that new users of medications had more 2.74 times greater 
probability of not acquiring their prescribed medications than prevalent users. The 
authors also found that maintenance (on going) medications had slightly higher 
probability of being acquired. Other studies found that a prescription of a new 
medication for a new medical condition has a lower probability of being filled in a 
pharmacy, comparing to a new medication prescribed for an ongoing condition109,111-112. 
 
Additionally, several studies on adherence to medications have demonstrated that many 
patients interrupt their treatment, shortly after the acquisition in a pharmacy of its first 
prescription11. This is called ‘early discontinuation’ or ‘short persistence’29,111.  
 
The failure to distinguish between the quality of execution or implementation while the 
patient is engaged with his or her dosing regimen and early discontinuation has led to 
the widespread belief that overall adherence in hypertension treatment is only about 50-
60%114. The distinction between these two aspects of the patients’ adherence to a 
prescribed regimen is crucial because the dynamics as well as the clinical and economic 
consequences of poor quality of execution and short persistence can differ markedly115.  
 
Different studies13,106,108 show that a substantially poorer medication adherence rate is 
observed when using a new prescription cohort, and accounting for those who fail to 
initiate the new medication (primary non-adherence), fail to ever refill (early 
discontinuation or short persistence), and time after discontinue treatment, rather than 
the more commonplace approach of only observing ongoing users.  
 
However, many adherence studies systematically exclude patients with primary non-
adherence or early non-persistence, since they rely on pharmacy dispensing or claims 
databases11,105. By definition, pharmacy claims databases do not contain information 
about medications prescribed but never dispensed (i.e., primary non-adherence). 
Furthermore, medications dispensed only once but never refilled (i.e., early non-
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persistence) do not meet the minimum criterion of two dispensings required to calculate 
the commonly used metrics for medication adherence calculations26,101-102,109. As a 
result, conventional adherence measures therefore systematically underestimate the 
public health burden of poor medication adherence for newly prescribed medications11. 
 
2.2.2. Second element of the adherence process: implementation 
 
Lapses in implementation occur in the context of ongoing treatment when patients 
modify their dosing regimen. They are typically a consequence of forgetfulness or 
negligence41,99 (i.e. non-intentional or non-intentional non-adherence): most of such 
errors involve a single day’s dose, but some represent ‘drug holidays’, which are an 
important aspect of patient non-adherence11,23,25,115. Drug holidays are a multi-day 
sequence of omitted doses, thus giving rise to exceptionally long intervals between 
sequential doses25,100,116. Still, the occurrence of longer lapses in dosing seems to be less 
frequently than shorter lapses115.  
 
Typically, there are six general patterns of implementation of dosing regimen: (1) close 
to perfect adherence; (2) taking nearly all doses with some timing irregularity; (3) 
missing an occasional single day’s dose, and some timing inconsistencies; (4) taking 
drug holidays 3 to 4 times per year; (5) taking drug holidays monthly or more often and 
have frequent omissions; and (6) taking few or no doses117-118.  
 
In addition, it is common for patients to improve their medication-taking behaviour 
shortly before and after an appointment with a healthcare provider, which has been 
termed ‘white-coat adherence’119-120. This phenomenon eloquently demonstrates the 
dynamics nature of medication-taking behaviour18. 
 
2.2.3. Third element of the adherence process: discontinuation  
 
Discontinuation marks the point in time when the patient stops taking the prescribed 
medication25. It occurs when the next due dose is omitted and no more doses are taken 
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Persistence is the continued use of a medication or medications (i.e. no discontinuation) 
for a specified period of time, quantified from the index date (first dose taken) until the 
date of treatment discontinuation. Persistence is commonly determined as a 
dichotomous variable for a specified period of time; for example, was a patient 
persistent at 6 months or at 1 year? The proportion of patients persistent at a given time 
and the average duration of persistence (i.e. the average time from treatment initiation to 
discontinuation) can then be calculated25,84. It implies that the patient must have 
exhibited at least primary adherence because persistence over time cannot be measured 
unless the patient has received at least the first dispensing101.  
 
Persistence can be defined in terms of medication persistence, regimen persistence or 
therapy persistence84.  
 
Medication persistence is the time on a given medication, from its initiation to the end 
of the study period or the end of the last dispensed prescription for that medication 
before discontinuation of that medication84. 
 
Regimen persistence is the time on a specified set of medications from initiation with 
that set to any change in the set of medications being received (additions or 
discontinuations) or the end of the study period. This metric is used to evaluate 
persistence with combination therapy involving two separate medications, for example, 
an ACEI and a diuretic that are not a single, combined drug. This approach goes beyond 
medication persistence in that the period of regimen persistence ends if any part of the 
overall treatment regimen is changed84. 
 
Finally, therapy persistence is the time on any medications, from initiation of therapy to 
discontinuation of all medications or the end of the study period. This metric is similar 
to that for medication persistence but allows for the duration of persistence to continue 
for the entire period that a patient receives any medication. It’s the most commonly used 
persistence definition used in the published literature59,84,93-95,121. In the case of 
hypertension treatment it is therapy persistence rather than medication persistence that 
matters93, due to substantial evidence that the major drug classes do not differ in their 
ability to protect against CV risk caused by hypertension4-7. 
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The use of any persistence definition implies that several types of changes in medication 
use should be accounted for, especially switching and additions. 
 
Switching refers to discontinuation of one medication with initiation of a new one at 
approximately the same time. ‘Approximately the same time’ is subject to 
interpretation; this can be within a specified window around the discontinuation event, 
based either on a fixed period of time (e.g. one month) or on the duration of one 
medication refill84.  
 
In hypertension treatment, early switching (i.e. shortly after initiation of a therapy) is 
likely to reflect adverse events, whereas switching after a longer period may reflect 
failure of reaching BP control. However, AHT drugs may also be switched if a patient 
develops other medical conditions (e.g. diabetes or congestive heart failure) and 
requires a different drug either to treat both hypertension and the new condition or to 
avoid contraindications with the new condition or other newly initiated drugs. 
Therefore, switching may not always indicate a treatment failure84.  
 
Additions of new AHT drugs may also represent clinical failures (i.e. inability to control 
BP using the current treatment regimen), although medications can be added to treat 
newly diagnosed conditions. However, additions do not affect evaluations of treatment 
adherence, because they do not involve changes in the use of the medication or 
medications being assessed. Furthermore, additions may or may not be considered 
failure events with respect to the determination of persistence, depending on the 
analysis being performed. In assessing medication persistence or therapy persistence, 
additions do not affect persistence, whereas the addition of new AHT drugs is viewed as 
discontinuation of the previous regimen in evaluating regimen persistence84. 
 
Lack of persistence often occurs when patients discontinue therapy without instructions 
from or even discussions with their healthcare provider. Whereas patients who rapidly 
achieve target BP generally show increased persistence, patients who do not achieve BP 
control or those who show some reluctance against the prescribed drug, experience 
adverse effects (or perceived them to be associated with the prescribed drug) or even 
don’t care with regard to provider’s instructions may be tempted to modify their 
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medication doses or just discontinue them. This may occur early in a course of therapy 
and generally there is no immediate symptomatic consequences of doing so84,86.  
 
In the context of life-long therapy like AHT therapy, discontinuation may occur in 
response to the prescriber’s decision to halt the treatment, but most often it is the result 
of a unilateral action by the patient, without the knowledge of the prescriber99,122. It has 
been estimated that during the first year of treatment up to 50% of patients discontinue 
their AHT therapy13,115,123-124. Most patients decide during the first year of treatment to 
continue or not and this decision is likely to last for a long time28. In an early study, 
among patients with newly diagnosed hypertension, for example, 78% were persistent at 
one year and only 46% at 4.5 years92.   
 
Because many patients may restart treatment at any point in time, Arnet et al115 
proposed the introduction of the quantification of reinitiation of treatment, as the 
proportion of patients with a dispensing after the predefined criteria for discontinuation 
(e.g. maximum ‘allowed treatment gap’ or ‘grace period’).  
 
 
2.3. IMPLICATIONS OF NON-ADHERENCE AND NON-PERSISTENCE ON CLINICAL 
PRACTICE 
 
On everyday clinical practice, if BP is not normalized with an initially prescribed 
regimen, prescribers may assume that the resulting lack of BP control is because of a 
lack of medication effectiveness rather than lack of medication use and respond by 
intensifying clinical measures with higher doses of medication - thereby increasing the 
risk of adverse effects, misdiagnoses, unnecessary treatment and further worsening of 
pre-existing illnesses – or  substituting the initial drug or adding another AHT 
drug29,56,83-84. Therefore, non-adherence and non-persistence may therefore lead to 
unnecessary adjustments of drug regimens, being early discontinuation a predictor of 
occurrence of changes of AHT therapy83. 
 
The physician is faced with a question: Did the drug fail or did the patient fail to use it? 
If the dose is increased, adverse effects could increase. If the drug is changed, the risks 
and costs of switching are incurred69. Burnier et al125 assessed patients presumed to 
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have drug-resistant hypertension. They found that nearly half of drug-resistant 
hypertensive patients were, indeed, non-adherents. The authors noted that “without any 
objective measurement of drug compliance, physicians have become used to opting 
almost always (...) for enhancing doses or prescribing new drug combinations (...) 
However, there is usually no rational basis for this decision”.   
 
So, starting with the assumption that patients with a variety of medical disorders take 
approximately half of medication as prescribed, prescribers should look for poor 
compliance, as a reason for ineffectiveness of a treatment69. However, there is little 
evidence that healthcare providers recognise patient adherence as an important factor in 
therapy; Heisler126 concluded that patient’s prior medication adherence has little impact 
on prescriber’s decisions about intensifying medications, even at very high levels of 
poor adherence. Many healthcare providers tend to overestimate their patient’s 
medication adherence29. 
 
A retrospective analysis of dosing histories of patients prescribed once a day AHT drugs 
showed that non-persistence is the leading problem with adherence: beside the fact that 
half of the patients stopped treatment within a year, 48% had at least one drug holiday a 
year and almost 95% of them missed at least a single dose a year; the better a patient 
executed the drug regimen, the more likely he/she was to persist with the prescribed 
dosing regimen115. Therefore, the persistence rate is an important element in 
determining the success of any long-term therapy. As mentioned, discontinuation of 
AHT therapy is associated with poor BP control24,61,127.  
 
Further, in pharmacy dispensing/claims database studies, it is usually not possible to 
determine whether discontinuation was prescriber-initiated or patient-initiated. Therapy 
or medication discontinuation in electronic database studies can only be assessed within 
the context of a pre-specified operational definition for the required number of days 
without medication available101 that distinguishes this behaviour from non-adherence84. 
This period is known as the maximum ‘allowed treatment gap’ or ‘grace period’82,85;115.  
 
Treatment discontinuation is typically defined as a gap of 30, 60 or 90 days or the time 
corresponding to two missed prescriptions between the end of 1 dispensed medication 
supply and any subsequent claim for the same medication25,84-85,93. A minimum of 60 
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days is generally used, because in many countries, many prescriptions include 30 days 
of supplied medication; 60 days without therapy would, therefore, indicate missing two 
adjacent prescriptions. If the standard duration of a prescription is different than 30 
days, it is recommended to use the time corresponding to 2 missed prescriptions as the 
minimum period for treatment discontinuation. For this calculation, only the amount of 
medication dispensed in the prescription immediately preceding the 60-day period 
should be considered. Medication leftover from previous prescriptions (i.e. when refills 
are made before the end of the days supplied) should not be used in determining 
treatment discontinuation84. 
 
Variation of the allowed treatment gap has a large influence on persistence rates and the 
proportion of persistent patients is more stable at larger maximum allowed treatment 
gaps, although more stable does not imply better reflecting actual discontinuation. The 
relation between the maximum allowed treatments gaps and the duration of the 
prescription is meant to decrease misclassification based on the length of a prescription 
a patient is receiving. When the goal of the study is to study persistence with drugs and 
compare different drug classes with each other, the maximum allowed treatment gap 
should be large, at least 90 days or one time the theoretical duration of the last 
prescription82. Thus, very low measured levels of adherence can in some circumstances 
represent, or are confused with, discontinuation101. 
 
 
2.4. RISK FACTORS FOR MEDICATION NON-ADHERENCE  
 
Medication-taking behaviour is extremely complex and individual, influenced by 
multiple factors, which requires numerous multi-factorial strategies to improve 
adherence to medications17. The published literature identifies hundreds of determinants 
of non-adherence. A recent review of systematic reviews identified 771 individual 
factor items associated with adherence to long-term treatment, the vast majority of 
which were determinants of implementation, and only 47 were found to be determinants 
of persistence with medication128. It is worth noting that this review, encountered 
difficulties due to the lack of standardized definitions, because many studies do not 
indicate the relative importance of the three elements of adherence to medications. 
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As discussed by the WHO in the report “Adherence to long-term therapies: Evidence 
for action”11, factors contributing to lack of adherence and/or persistence can be divided 
in five categories: socioeconomic, condition-related, therapy-related, patient-related, 
and healthcare team and system-related factors. 
 
2.4.1. Socioeconomic factors 
 
Many reviews reported a positive effect of family and social support on adherence, and 
a negative effect of the lack of such support128. A meta-analysis of 122 studies, 
conducted by Scheurer et al129, aimed at assessing which type of social support 
(practical, emotional or undifferentiated) had the strongest relationship with adherence, 
found that practical social support (i.e. supervision of medication administration by 
others) yielded significantly higher effects than emotional and undifferentiated support.  
 
Economic factors such as unemployment, low income, poverty, lack of, or inadequate 
medical/prescription coverage, as well as high out-of-pocket costs of prescribed 
medications may seriously contribute to non-adherence11;17;67;128;130. 
 
One of the best documented barriers to adherence to medications is high out-of-pocket 
costs. Numerous studies have found that increased medication co-payments are 
associated with decreased use of prescribed medications, even for highly effective ones 
used to treat chronic conditions, such as hypertension56;65-66;102;110-112;131-132.  
 
Choudhry et al132 found that the odds for full adherence to CV medications increase, 
even though modestly, by upward the coverage for medications.  
 
However, the higher rate of adherence to ARBs compared with diuretics found in a 
meta-analysis on the impact of drug class on adherence to AHT, suggests that drug cost 
plays a relatively minor role in AHT adherence. The authors argue that it is possible that 
cost plays a more significant role in underinsured populations in which medication users 
are responsible for a significant portion of prescription costs19.  Also, cost is less an 
issue now than in the past because many AHT drugs are available in generic form, 
which reduces its impact13 because as Shrank et al107 demonstrated, adherence is greater 
for generic drugs compared to brand name, and more expensive ones.  
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Shrank’s107 findings are not consensual and applicable to all conditions. Briesacher et 
al131 found that although generic prescribing was associated with modestly improved 
adherence in some conditions (hypothyroidism and hypercholesterolemia), for 
hypertension it was associated with poorer adherence. Corrao et al133 found that patients 
who started AHT therapy with generics did not experience a different risk of 
discontinuation compared with those starting on brand name agents. 
 
Still, in Portugal a survey conducted for the Spring Report 2013134, demonstrated that 
more than half of patients mentioned that have replaced their usual medications for less 
expensive ones; 13.3% stated to fully stop taking their medications and 15.8% 
mentioned that they have started to take less dosages, in order to hoard their 
medications. The authors of the report found that this was more common for statins, 
AHT and antidepressants.  
 
2.4.2. Condition-related factors 
 
Adherence relates to condition. Asymptomatic nature of the disease may reduce patient 
motivation to take their medications as prescribed, whereas disease severity may have a 
positive effect on adherence56;67;128;130.  
 
Adherence rates are rather low in preventive treatment and/or in conditions under which 
a long abstinence may not immediately be followed by serious consequences93. 
Previous studies have also demonstrated that adherence to medication continues to 
decline even after a stroke17; thus it is not surprising that treating asymptomatic 
conditions to prevent the possible occurrence of adverse events years later presents an 
even greater challenge.  
 
Hypertension is largely asymptomatic, and patients often have a poor understanding or 
may lack awareness of the long-term consequences of elevated BP or the importance of 
BP control11;17-18;35;66;127;130;135-136.  
 
Additionally, many patients with hypertension remain free of symptoms after the onset 
of this chronic condition. However, treatment itself produces adverse effects in some 
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patients56;66;127, and therefore, non-adherence has been reported to increase with any 
adverse effects and with increasing numbers of adverse effects (even with patients' 
perceptions of adverse effects17). Adverse effects like dry cough, dizziness, nausea, and 
headache associated with some AHT drugs may interfere with adherence, because 
patients weigh these immediate problems against the long-term benefits of treatment127. 
In a study performed in Portugal on medication adherence, patients’ responses to the 
questionnaires showed that the main reasons for non-adherence related to the drugs 
themselves were adverse effects and symptomatic improvement followed by 
discontinuation82. 
 
This non-adherence to medications secondary to adverse effects is termed ‘rational non-
adherence’, which Garner137 defines as “the cessation of a prescribed therapy because of 
concern for, or the presence of, medication side effects”. The author further states that 
rational non-adherence “is nearly impossible to circumvent if a patient’s specific side-
effect concerns are not substantially addressed”. Therefore, it is critical that adverse 
effect profiles are considered when prescribing a medication and discussed with the 
patient before the initial prescription and at every visit thereafter17.  
 
Adherence to medication also involves adopting and maintaining medication-taking 
behaviours that may change the daily routine. Due to the lack of symptoms, treatment 
may not be perceived by the patient as absolutely necessary67.  
 
2.4.3. Therapy-related factors 
 
If treatment is patient unfriendly, due to its complexity, the likelihood of patient 
adherence drops11;26;56;63;66;112-113;138-141. The complexity of the prescribed regimen 
consists of three major domains: the number of medications prescribed; the complexity 
of administration, and daily dosing frequency142.  
 
The need to take many different medications and/or the complexity of the prescribed 
regimen was the main reason for non-adherence in 8.7% of patients, in the study 
conducted by Cabral and Silva82. Even for those who did not indicate complexity of the 
therapy as the main reason for non-adherence, it was considered an important factor 
affecting adherence by over 40%.  
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Subsequently, the simplification of daily dosing frequency has a high potential to 
improve medication adherence in patients with hypertension24;140. Simplified dosing 
regimens can result in improvements on adherence to medications between 8% and 
almost 20%50. Several studies22;62;66;68;89;138;140;143 have confirmed the inverse 
relationship between medication adherence and the prescribed number of doses per day, 
also in the hypertension setting as well. A meta-analysis including data from 11.485 
patients demonstrated that the average adherence rate for QD dosing was significantly 
higher than for BID (twice a day) dosing in hypertension142. Another systematic review 
conducted in Portugal, showed that QD dosing vs. BID or higher dosing was associated 
with a reduction of 56% in risk of non-adherence to treatment68.  
   
In addition to the complexity of the therapeutic regimen, a longer duration of the 
treatment may also affect negatively adherence to medication128;130;142. The meta-
analysis of Iskedjian et al142 also demonstrated that, the longer the therapy lasted, the 
lower the adherence rates.  
 
Polymedication, as in an excessive number of prescribed medications also as a negative 
effect on adherence due to the increased risk of toxic and/or adverse effects of 
medications128;144. 
 
Mazzaglia et al63 observed improved adherence (≈30%) associated with combination 
therapy compared with monotherapy, which supports that the use of low-dose 
combinations favours adherence because of the smaller side effects compared to full-
dose therapy5;138. The combination should preferably contain long-acting substances to 
maximize forgiveness against brief periods of dose omissions50. Studies have 
demonstrated that the use of single-pill combinations has some advantages. But it also 
has drawbacks. Indeed, if the patient omits several consecutive doses of a single-pill 
combination, he/she actually misses two or three drugs simultaneously, increasing the 
risk of hypertension rebound effects97. However, although single-pill combinations have 
been shown to improve execution or implementation, the impact on persistence is only 
modest, with a 10% to 20% improvement over 1 year145. 
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Pharmacy refill and claims data suggest that there are differences in adherence among 
the most commonly prescribed AHT drug classes. Compared to ARB agents, ACEIs, 
and CCBs, thiazide diuretics, and BBs have increased gaps between prescription refills 
and are more likely to be discontinued66;91, possibly due to increased adverse effects of 
medications from these classes19;86;90;143. Diuretics, for example, can cause urinary 
frequency, erectile dysfunction, fatigue and muscle cramps. They can also produce 
metabolic and electrolyte abnormalities that may lead physicians to discontinue those19. 
Adverse effects reported with ARBs are substantially lower than those reported for 
other classes of AHT50.  
 
Some studies have shown that persistence with AHT treatment depends largely on the 
choice of the initial drug class59;66;91-92. According to a recent meta-analysis, mean 
persistence to AHT medications was 65% for ARBs vs. only 28% and 51% for BBs and 
diuretics, respectively. The authors found a remarkable degree of consistency in the 
demonstration of superior adherence to ARBs and ACEIs and inferior adherence to 
diuretics and BBs19. The association between BB and non-adherence may also be likely 
explained by the increased propensity for the first to be prescribed as multiple doses per 
day143. Another possible explanation for the differences in adherence by drug class may 
be variation in provider and patient beliefs about medications19. 
 
2.4.4. Patient-related factors 
 
Several patient-related factors, including lack of understanding of their disease, lack of 
involvement in the treatment decision-making process, and suboptimal health literacy, 
contribute to medication non-adherence17;56;128.  
 
A recent systematic review and meta-analysis of epidemiological studies demonstrated 
that a low health literacy is one of the factors which significantly influence adherence 
levels (in a subset of studies with relevant information), a long side with low social 
status56. Also, higher income has small yet positive effects on adherence146. 
 
As mentioned, patients may have a poor understanding or may lack awareness of the 
long-term consequences of elevated BP or the importance of BP control, particularly 
because hypertension is often asymptomatic (e.g. no immediate physical symptoms 
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resulting from missing doses, on either an occasional or permanent basis, are 
apparent)11;17-18;35;127;130;136. However, inadequate health literacy is often under 
recognized and therefore not addressed by healthcare providers17.  
 
Lack of awareness may be particularly relevant for newly diagnosed hypertensive 
patients, who generally have lower persistence rates than patients with established 
hypertension27. Patient’s awareness of their adherence patterns can change their 
medication-taking behaviour. A review and meta-analysis of adherence enhancing 
interventions in 79 RCT, showed that feedback to patients about their medication-taking 
patterns was the biggest factor influencing adherence147. 
 
The patient’s health beliefs and attitudes concerning the effectiveness of the treatment, 
such as beliefs about the efficacy of treatment; “being tired” of taking medications 
and/or perceived excessive medication use; their previous experiences with 
pharmacological therapies, and lack of motivation also affect the degree of adherence to 
medication11;17. A belief that the medical condition in question was a threat because of 
its severity may increase adherence128.   
 
Within this context, a key component of any adherence-improvement plan should be 
patient education. The more empowered patients feel, the more likely they are to be 
motivated to manage their disease and adhere to their medication. Thus, actively 
involving patients in treatment decisions when possible is also a factor to consider17.  
 
Several determinants, including age and gender are known to be associated with 
discontinuation of AHT therapy66;85-86. Older patients tend to continue longer treatment 
than younger patients and male patients tend to show more persistence than female 
patients66.  However, age and gender were found to have an inconsistent impact on the 
implementation of correct dosing128.  
 
2.4.5. Healthcare team and system-related factors 
 
Inefficient health systems, with insufficient distribution of medication, lack of 
knowledge and education of healthcare professionals regarding specific chronic 
diseases, the limited time for consultation and availability for follow-up, lack of 
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incentives, the inability to evaluate patient’s level of adherence to medications and its 
impact on health indicators, are of paramount importance and interfere with adherence 
to prescribed therapies67. 
 
Not only do physicians often fail to recognize medication non-adherence in their 
patients, they may also contribute to it by prescribing complex drug regimens, failing to 
explain the benefits and adverse effects of a medication effectively, and inadequately 
considering the financial burden to the patient17;23. Ineffective communication between 
the physician and the patient with a chronic disease such as hypertension further 
compromises the patients understanding of his or her disease, its potential 
complications, and the importance of adherence to medication17.  
 
The substantially improved adherence of patients who report a good relationship with 
their physician highlights the important role of physicians in the medication adherence 
process23;148-151. The risk of nonadherence is 19% higher in patients whose physician 
communicates poorly compared with patients whose physician communicates well148. 
Healthcare provider’s ability to demonstrate empathy has a positive effect on adherence 
to medication130;149 because it promotes trust and respect and enhances motivation of 
patients to take medications13. Persistence rates are directly correlated with a strong and 
trusting physician-patient relationship66.  
 
By asking the appropriate questions, physicians can accurately access which 
medications patients are taking and how they are taking them17;149. Questions such as17:  
i. I know it must be difficult to take all your medications regularly. How often do 
you miss taking them?  
ii. Of the medications prescribed to you, which ones are you taking? 
iii. Of the medications you listed, which ones are you taking?  
iv. Have you had to stop any of your medications for any reason?  
v. Have you noticed any adverse effects from your medications? 
 
However, physicians often do not ask about medication adherence. Lack of time, doubt 
that low adherence is a cause of uncontrolled BP, and uncertainty about how accurately 
determine adherence and use this information in clinical practice are some of the 
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limiting factors for physicians considering adherence in their clinical decision-
making150.      
 
Different studies35;151 have demonstrated that medication adherence is the most likely 
independent variable to be positively influenced by an healthcare professional, in order 
to improve BP control.  
 
Another healthcare team factor that may influence adherence to medication is the 
number of prescribers involved in the management of chronic diseases, such as 
hypertension. Barat et al152 found that the risk of non-adherence increased when patients 
get prescriptions from more than one prescriber.  
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An appropriate quantification of adherence to medications constitutes the basis for 
adherence-related sciences, by informing the process of managing adherence, the aim of 
which is to help patients to take appropriately prescribed drug dosing regimens25.  
 
It should be made by using a clear and precise taxonomy and provide meaningful 
metrics which should be reliable, allow tracking over time, be coherent with the three 
elements of medication adherence and be implementable on a large scale122. It is well 
known that adherence to medications is often misclassified and poorly quantified, and 
that can lead to both erroneous conclusions regarding the efficacy of treatments as well 
to dose-response relationships which will ultimately impact on patient care with serious 
adverse consequences on patient care153. The ultimate goal is optimal pharmacotherapy 
and its implicit association with optimal clinical outcomes25. 
 
Although rates of adherence for individual patients are usually reported as the 
percentage of the prescribed doses of the medication actually taken by the patient over a 
specified period of time23;26, the difference introduced by the construct of medication 
adherence as a dynamic process precludes a single, quantitatively useful parameter to 
cover all three components. Previous studies have shown major differences in the 
dynamics of the three components of adherence to medications over time, which can 
reveal different causes and/or consequences25.  
 
The majority of studies tend to employ indirect measures of adherence and categorize 
the medication use during the course of therapy into either “good” or “poor” levels of 
adherence30;56. On hypertension studies, a threshold value of 80% is commonly used23-
24;26;56;91;111;129;137-138;141;153, which is close to the average adherence value, 76%, reported 
by Cramer68 across several studies of AHT drugs and has been accepted as the most 
conventional and widely reported cut-off for optimum adherence55.  
 
Still, some authors argue that setting arbitrary cut-offs, such as 80%, are sometimes of 
little clinical interest for many reasons. One of them is that an adherence of 80% can be 
achieved in many different ways, each with a very different clinical impact (e.g., one 
missed dose every five days or one missed week of doses every five weeks).  
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Vrijens, Urquhart and White72 have demonstrate that using data collected electronically 
during a three-month period for patients prescribed with BID doses. Figure 2 shows 
drug dosing histories for four patients, each of whom took 75% of their prescribed drugs 
during the three-month period. The blue dots represent taken doses and vertical grey 
bars represent omitted doses. The first three patients display partial implementation: (A) 
patient mainly missed evening doses; (B) patient missed both evening and morning 
doses; (C) patient display a drug holiday; (D) patient initially had a high level of 
adherence, but discontinued therapy prematurely. 
 
 
Figure 2. Differences in adherence patterns (figure from Vrijens, Urquhart and White71) 
 
Furthermore, no one really knows what level of adherence is sufficient to obtain the full 
benefit of a medication because medications were rarely investigated in this respect. 
Thus, depending on the pharmacological characteristics of the prescribed drug, 80% of 
prescribed doses taken may be sufficient or not for full therapeutic benefit97.  
 
There are many different methods for measuring adherence to medications. Osterberg 
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Table 2. Methods of measuring adherence to medications 
METHOD ADVANTAGES DISADVANTAGES 
Direct methods 
Directly observed therapy Most accurate  
Patients can hide pills in the 
mouth and then discard them; 
impractical for routine use 
Measurement of the level of 
medicine or metabolite in the 
blood 
Objective 
Variations in metabolism and 
“white-coat adherence” can 
give a false impression of 
adherence; expensive method 
Measurement of the biological 
marker in blood 
Objective; in RCT can be 
used to measure placebo 
Requires expensive 
quantitative assays and 
collection of bodily fluids 
Indirect methods 
Patient questionnaires; patient 
self-reports 
Simple; inexpensive; the 
most useful method in 
clinical setting 
Susceptible to error with 
increases in time between 
visits; easily distorted by 
patients 
Pill counts 
Objective, quantifiable, and 
easy to perform 
Data easily altered by the 
patient (e.g. pill dumping) 
Rates of prescription refills 
Objective; easy to obtain 
data 
A prescription refill is not 
equivalent to ingestion of 
medication; requires a closed 
pharmacy system 
Assessment of the patient’s 
clinical response 
Simple; generally easy to 
perform 
Other factors besides 
medication adherence can 
affect clinical response 
Electronic medication monitors 
Precise; results are easily 
quantified; tracks patterns 
of taking medication 
Expensive; requires return 
visits and downloading data 
from medication vials 
Measurement of physiological 
markers 
Often easy to perform 
Marker may be absent for other 
reasons (e.g. increased 
metabolism, poor absorption) 
Patient diaries 
Help to correct for poor 
recall 
Easily altered by the patient 
Adapted from Osterberg and Blaschke23 
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Although direct methods are considered to be more robust than indirect methods, they 
also have some limitations. All these methods differ with regard to their validity, 
reliability and sensitivity23 and none of them provide 100% robust data60;74. 
 
Also what is ‘measured’ is not the same in every method. Rates of prescription refills, 
for instance, measure medication acquisition, which is different than medication 
consumption, measured by pill counts, physiological markers, or electronic medication 
monitors30.  
 
Much effort has gone into devising methods for reliably quantifying ambulatory 
patients’ adherence to prescribed medications, especially those intended for long-term 
use against various major chronic diseases25.  
 
The best of the available methods provide for the reliable capture, storage, analysis, and 
communication of dosing history data in ways that make it difficult or impossible for 
patients or trial staff to censor or otherwise manipulate the data. Methods that meet 
these criteria include the following: (1) retrospective analysis of prescription refill 
records (i.e. pharmacy refill rates), (2) analysis of chemical markers of drug exposure, 
such as the level of the medicine or its metabolite in the blood and (3) electronic 
medication monitors with automatic electronic time-stamping and compilation of events 
more or less strongly linked to the act of medication-taking (e.g., package opening, 
dosage form dissolution)29;115.  
 
Other methods, such as questionnaires, interviews, and periodic counts of patients’ 
returned, untaken doses, are subject to many uncertainties and easy manipulation by 
patients25. Electronic monitoring of adherence, for instance, has shown that pill counts 
overestimate medication consumption30. A recently published paper also demonstrated 
that objective urinary drug levels quantification by liquid chromatography mass 
spectrometry does not overlap with questionnaire results. An objective quantification of 
adherence shows a higher rate of non-adherent patients155. 
 
Until recently there was no scientific justification to considerer one of these as the ‘gold 
standard’23;74. Electronic methods for compiling drug dosing histories have emerged as 
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the currently recognized standard for quantifying adherence72 even though its utilization 
is not widespread, especially due to the costs associated and its potential for patients to 
manipulate the device125.  
 
Although electronic monitoring of adherence increases measurement accuracy, in the 
context of implementation24, for evaluation of initiation and implementation in real 
world conditions, prescription and refill databases are the best method122 (Table 3).   
 
Table 3: Advantages and disadvantages of methods of measuring adherence to 
medications 
 INITIATION IMPLEMENTATION DISCONTINUATION 
Self-report Desirability bias Recall bias Desirability bias 








Requires sampling after 
prescription 
Sampling is too sparse 




Gold standard if both 
databases are combined 
Only aggregate 
summary 




Gold standard in 
clinical trials needs 
activation 
Gold standard 
Gold standard in 
clinical trials needs 
patient engagement 
Adapted from Vrijens and Heidbuchel118  
Legend:  PK/PD – pharmacokinetics/pharmacodynamics 
 
 
3.1. RATES OF PRESCRIPTION REFILLS  
 
As mentioned, rates of pharmacy refill, extracted from pharmacy dispensing/claims 
databases, can be used as a surrogate for adherence to medications, since they reflect 
patients’ decision to continue with their prescribed therapy and patients’ effort to obtain 
the medication as the first step toward taking it34. By assessing whether patients acquire 
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Pharmacy dispensing/claims databases have several known advantages: (1) they are not 
subject to memory bias156-157; (2) data access and collection is done electronically31;33;85 
and therefore, in a relatively easy manner67;85; (3) it’s accuracy is high33; (4) lower costs 
compared to other methods33;67;85;157; (5) large populations of patients can be followed 
over long periods of time31;67; (6) it’s not required any informed consent from 
individuals for data collection32, because studies can be accomplished with de-
identification of patients158-159, thus protecting their privacy31;33;157. 
 
However, such databases also have some disadvantages: (1) prescription records aren’t 
always reflected in claims records; (2) dispensing does not necessarily means actual 
use33;156;159; (3) the duration of use can’t always be predicted from package size or 
theoretical dosage regimen156; (4) missing information on over-the-counter 
medication33;156;159, self-medication156 and drugs dispensed in hospitals33; (5) data 
sources not designed for research31; (6) the information on individuals is usually 
sparse33 – missing data elements, unmeasured confounders and data quality and 
integrity may not be the same across the database, namely by misclassification of drug 
exposure and/or outcomes or even diagnostic misclassification31. 
 
Within such limitations, refill rates cannot clearly determine whether a patient does not 
adhere to their prescribed medications because he or she has not followed up with the 
provider to receive a new prescription, the provider has not written the prescription, the 
prescription was written but not delivered to the pharmacy, or the prescription was 
delivered to the pharmacy but not fully picked up (i.e. prescription for two packages but 
only one was acquired by the patient)107. 
 
Although the use of pharmacy dispensing/claims databases has a number of limitations, 
its relative efficiency for studies of adherence and persistence in large populations in a 
real-world setting is highly advantageous23;26;67;109.  
 
Prescription refill records are only a valid source of information about medication-
taking behaviour when the database is complete; if the patient uses a pharmacy not 
linked to the database, then it can lead to incomplete and erroneous calculations18. If 
that’s not the case and patients are unlikely to obtain the medications from other sources 
not captured by the database, the estimates derived from studies using automated data, 
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3.2. METRICS USED TO CALCULATE MEDICATION ADHERENCE AND PERSISTENCE 
 
In general, the metrics that have been used to calculate medication adherence and/or 
persistence enable calculation of either medication possession (i.e., possession 
measures) or gaps in medications availability (i.e., gap measures)26;160-162 and most 
estimate adherence only among individuals with secondary adherence, as previously 
mentioned. Table 4 displays different medication adherence measures that have been 
used in studies with pharmacy refills.  
 
Most metrics are continuous measures, but they are often categorized (e.g., low or 
inadequate versus moderate versus high or adequate adherence)23-24;26;30;56;91;105;131;139-
140;143;152-153.  
 
These measures require data including the date of medication dispensing, days’ supply 
dispensed with each dispensing, and previous (stockpiled) medications (or an indication 
that it will be set to zero) to estimate medication availability and consumption. The 
metrics also vary in whether or not the days’ supply dispensed with the terminal 
dispensing is included in the calculation. The time between any one dispensing and the 
subsequent dispensing is known as the refill interval. Person-time is censored at the last 
dispensing date, at the time of exhaustion of the last days’ supply, or at a fixed number 
of days after exhaustion of the last days’ supply. Most gap measures of secondary 
adherence censor after the last dispensing once stockpiled medications have been 
exhausted30;101.   
 
The assumption beneath the maximum medication gap is that these gaps are due to 
reduced adherence rather than to clinicians’ instructions for temporary or permanent 
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Table 4. Adherence measures reported in pharmacy refill studies 





cumulative days’ supply of 
medication obtained / total 
days to next fill or to end 
of observation period 
adherence value for 





of Medication Gaps 
total days of medication 
gaps / total days to next fill 
or end of observation 
period 
non-adherence value for 
cumulative period, 






Interval Measure of 
Oversupply 
(total days of medication 
gaps - leftovers) / total 
days in observation period 
non-adherence value for 
cumulative period, 






interval measure of 
Medication 
Acquisition 
days’ supply obtained at 
beginning of interval / days 
in interval 
adherence value for 







days’ supply / days in 
period 





Proportion of Days 
Covered 
(total days’ supply/total 
number of days evaluated) 
x100, capped at 1.0 







[sum of quantity dispensed 
over interval / quantity to 
be taken per day) x100] / 
number of days in interval 






total days of the maximum 
medication gap / total days 
in observation period 





Adapted from Andrade23, Steiner and Prochazka30 and Vink162 
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The most frequent statistics used for quantifying, within a patient, the implementation 
of a dosing regimen, over a defined period of time, are: (1) the proportion of prescribed 
drug taken; (2) the proportion of days with the correct number of doses taken; (3) the 
proportion of doses taken on time, in relation to a prescription-defined time interval 
between successive doses; (4) the distribution of inter-dose intervals; (5) the number of 
drug holidays; and (6) the longest interval between two doses25. 
 
Within such statistics, the two most commonly used secondary adherence medication 
possession measures are the Medication Possession Ratio (MPR) and the Proportion of 
Days Covered (PDC)26,84,100,160-162. Both report medication availability by estimating the 
proportion of prescribed days’ supply obtained during a specified observation period 
over refill intervals. Both MPR and PDC correlate well with the quantity of doses taken 
but not with the timing of the doses, and the quantification of adherence with these 
metrics is more difficult when the length of follow-up varies between patients100.  
 
The main difference between the PDC and the MPR is that with the PDC any 
oversupply is truncated, whereas adherence values of greater than 100 percent are 
allowed with the MPR. There is controversy about whether ‘over adherence’, often 
considered as MPR between 100 and 120 percent, has clinical meaning101. Although a 
MPR over 100% may reflect patients refilling prescriptions before the end of their 
medication supply or hoarding medication for later use, it is unlikely that patients will 
actually use AHT drugs at greater than the prescribed frequency. Therefore, MPR 
should also be capped at 100%26.  
 
The systematic review conducted by Andrade et al26 demonstrated that within the 
majority of studies, MPR is estimated as the day’s supply of medication dispensed 
during a specific follow-up period (e.g. one year) divided by the number of days from 
the first dispensing to the end of the follow-up period.  
 
Many pharmacy dispensing/claims databases do not provide information on days 
supplied for prescriptions but do include amount dispensed; to determine MPR or PDC, 
the number of pills dispensed and doses per day (either from the database or from 
standard medication references) can be used to estimate the number of days 
supplied26,84. 
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Several limitations to MPR calculations are related to the nature of retrospective 
databases. For example, patients may obtain the medication(s) of interest from sources 
not captured in the available data, such as sharing medication with others (e.g. family 
members). The main limitation to MPR calculations (i.e. not related to retrospective 
data) is the assumption that the proportion of days covered by a prescription 
corresponds to the proportion of days of medication use. Patients may fill prescriptions 
at regular intervals yet not take the medication in the manner prescribed. Nevertheless, 
MPR is the accepted standard for the evaluation of adherence using retrospective data; 
it’s easy to calculate, it’s a well-established objective measure of pharmacy refill 
adherence and is the most commonly used metric, allowing for comparisons among 
studies. Therefore, MPR is the best available measure for assessing adherence to AHT 
medications using retrospective data34. 
 
In terms of persistence, Caetano et al163 identified five different methods for calculating 
persistence: anniversary models, minimum-refills models, refill-sequence models, 
proportion-of-days-covered models, and hybrid models. When these models were 
applied to data for a hypothetical patient, a wide range of values and interpretations 
resulting in a total persistence with drug therapy ranged from 7 days to >1 year. The 
authors stated that a standard operational definition of persistence should be bi-
dimensional, quantifying not only the total duration of therapy, but also the intensity of 



























The main objective of this thesis is to determine adherence to antihypertensive therapy 
in newly diagnosed and treated hypertensive patients in Primary Health Care units of 
Lisbon and Tagus Valley Health Region. 
 
SPECIFIC OBJECTIVES (PRIMARY): 
 
i. Determine the rate of primary adherence to prescribed AHT drugs; 
ii. Determine the rate of initiation of AHT therapy;  
iii. Determine the rate of implementation of AHT therapy in the observation period; 
iv. Determine the rate of two-year persistence to AHT therapy. 
 
SPECIFIC AIMS (SECONDARY): 
 
i. Identify risk factors for non-initiation of AHT therapy;  
ii. Identify risk factors for poor quality of implementation of AHT therapy;  
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5.1. LOCAL CONTEXT 
 
Data analysed in this thesis were collected from the information system of the Regional 
Health Administration of Lisbon and Tagus Valley (ARSLVT). Lisbon and Tagus 
Valley Region is a region of Portugal which accounts for about 13% of the Portuguese 
territory and 34.6% (3.7 million) of its population164.  
 
In Portugal, healthcare is provided by two overlapping systems: a publicly funded 
National Health Service (NHS) and voluntary private and public health insurance. The 
NHS has universal coverage, and 20% of the population has additional insurance 
coverage165. In spite of that, the costs with reimbursement of prescribed drugs of 
voluntary private and public health insurance in Portugal have been decreasing over the 
last years, representing in 2011, less than 12.5% of the NHS total costs with 
reimbursement of prescribed drugs166. 
  
Electronic prescribing is mandatory for all NHS reimbursed drugs regardless the health 
care providing system since 2010167. A report from the Portuguese Ministry of Health 
(data of the period between February 2011 and June 2012) shows 98.7% of electronic 
ambulatory prescriptions in the PHC sector; 97.7% in public hospitals and 73.7% in 
private practice168. 
 
Drug prescriptions must include the International Non-proprietary Name of the active 
substance, its pharmaceutical form, the strength, the presentation (package size) and the 
dosage regimen. All prescriptions information is collected centrally by the NHS169. 
However, since the inclusion of the dosage regimen is not mandatory for prescription 
validation, that specific information is not always registered. 
 
For acute situations, drug prescriptions are valid for a 30-day period after the date of the 
prescription – single prescription with a maximum of two packages per drug. For 
chronic conditions, the prescription can be renewed up to three times – three identical 
prescriptions with a maximum of two packages per drug to be dispensed within six 
months after the date of the prescription169.   
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Community pharmacies then submit electronic claims for reimbursement of the NHS 
and/or voluntary private and public health insurance funded components of dispensed 
drugs to a centralized reimbursement system, in functions since March 1st, 2010.  All 
reimbursed drugs are registered here170.  
 
For AHT drugs – the focus of this thesis – reimbursement corresponds to 69% of the 
reference price of the homogeneous group, when applicable, or 69% of the 
Recommended Retail Price (RRP) when the drug is not included in a homogeneous 
group171.  
 
The linkage between prescriptions and dispensing/claims data can be made through the 
information system of the Regional Health Administration – SIARS, which is an 
administrative database, developed to facilitate analysis and monitoring PHC units’ 
activity and production. This automated system includes information on diagnosis made 
and registered at PHC units, as well patients’ demographic and administrative data.  
 
 
5.2. STUDY DESIGN 
 
We’ve conducted an observational study, more specifically a retrospective cohort study. 
We used a cohort of newly diagnosed and treated hypertensive patients, within the PHC 
units of Lisbon and Tagus Valley Region. We identified all patients – aged between 18-
90 years – who were diagnosed with hypertension and received a first prescription 
(index prescription) for at least one AHT drug during the first trimester of 2011 - Jan 1st 
to Mar 31st.   
 
Hypertension was defined in the terms of codes k86 - Hypertension uncomplicated – 
and k87 – hypertension complicated – of the International Classification of Primary 
Care, 2nd ed. (ICPC-2)172. 
 
AHT drug classes for which the several adherence rates were determined, with 
corresponding anatomical therapeutic chemical (ATC) classification system codes were: 
- C02: Antihypertensives  
o C02A: antiadrenergic agents, centrally acting 
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o C02C: antiadrenergic agents, peripherally acting 
- C03: Diuretics 
o C03B: low-ceiling diuretics, excl. thiazides 
o C03C: high-ceiling diuretics 
o C03D: potassium-sparing agents  
o C03E: diuretics and potassium-sparing agents in combination 
- C07: Beta blocking agents 
o C07A: beta blocking agents 
- C08: Calcium channel blockers 
o C08C: selective calcium channel blockers with mainly vascular effects 
o C08D: selective calcium channel blockers with direct cardiac effects 
- C09: Agents acting on the renin-angiotensin system 
o C09A: ACE inhibitors, plain 
o C09B: ACE inhibitors, combinations 
o C09C: angiotensin II antagonists, plains 
o C09D: angiotensin II antagonists, combinations 
o C09X: other agents acting on the renin-angiotensin system. 
 
Within each class, only drugs indicated for the treatment of hypertension (as expressed 
by each Summary of Product Characteristics – SmPC) were analysed.  
 
Prescriptions and claims (drugs dispensed with a prescription) data of AHT drugs were 
collected for every patient for a two-year follow-up period after index date, i.e. the date 
of first acquisition of at least one AHT drug in a community pharmacy.  
 
 
5.3. STUDY POPULATION 
 
Study population consisted of all patients diagnosed with hypertension and newly 
treated for that condition during the first trimester of 2011 in the PHC units of Lisbon 
and Tagus Valley Region, with no prior use of AHT drugs until January 1st 2011. 
 
To determine whether patients were truly new users of AHT therapy, prescriptions and 
claims data were collected additionally for a period of 6 months prior to January 1st 
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2011. Therefore, patients with no prescriptions and/or no claims records for any AHT 
drug in the 6-month period before January 1st 2011 were classified as newly treated 
patients (new users), whereas those who received prescriptions for AHT drugs in this 
run-in period were classified as established users and weren’t include in the cohort.  
 
5.3.1. Exclusion criteria 
 
- Patients outside the defined age range (18-90 years). 
- Patients with at least one prescription and/or claim record prior to Jan 1st 2011, 
i.e. established users. 
- Patients with an index date prior to the index prescription (an index date prior to 
the index prescription makes it impossible to determine time to initiation). 
 
 
5.4. EXPOSURE DEFINITIONS AND ADHERENCE MEASURES 
 
Exposure to AHT therapy was defined as the duration of all dispensings of AHT drugs, 
per patient, within the observation period, starting from initiation (set by the index date) 
and ending at discontinuation or the end of the observation period, whichever occurred 
first. 
 
5.4.1. Rate of primary adherence 
 
The rate of primary adherence was expressed as the number of claims records divided 
by the total number of prescriptions records. This was done considering that each claim 
corresponds to a single AHT drug package.  
 
Primary adherence rate reflects only patients’ acquisition of prescribed AHT drugs26,102, 
meaning that a prescribed drug was dispensed within the legal defined number of days 
after it was prescribed.  
 
By opposition, primary non-adherence was defined as the absence of a claim record for 
a prescribed AHT drug102.   
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We compared primary adherence rates across patients’ characteristics, such as gender, 
age, region, buying power and ICPC-2 code of diagnosis, as well across drug classes 
and other drug characteristics, such as its classification as generic or brand name drug 
and out-of-pocket costs.  
 
Bivariate analysis was conducted to determine which characteristics were related to 
primary adherence. Categorical variables were analysed using the chi-square test.  
 
5.4.2. Initiation  
 
In this thesis, initiation was evaluated as a dichotomous event (patient initiates therapy: 
yes/no) but also as a time-to-event variable.  
 
In the first analysis, initiation was quantified as the proportion of patients not exceeding 
the six-month period after index prescription (i.e. new users of AHT therapy), which is 
the maximum allowed period of time for dispensing of a prescribed drug in a 
community pharmacy in Portugal169. 
 
In the second analysis, time to initiation (time-to-event variable) was defined as the 
length of time from index prescription (time origin) to index date (end-point) within the 
six-month period after index prescription. The index date was used as a proxy for first 
dose taken25.  
 
Initiation of treatment was analysed by Kaplan-Meier survival analysis, determining the 
time to initiation for each patient. Patients were censored six-months after the index 
prescription. Estimates of time to initiation were assessed for the potential predictors of 
initiation of treatment including age, gender, and pharmacological class, number of 
drugs initially prescribed, patients’ buying power, ICPC-2 code and out-of-pocket costs 
of the prescribed AHT drugs.  
 
Cox proportional hazard regression (including all potential predictors mentioned above) 
was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for 
initiation. The significance threshold was set at 0.05. 
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5.4.3. Implementation  
 
Implementation was defined as the extent to which a patient’s actual dosing regimen 
corresponded to the prescribed dosing regimen25, throughout the two-year observation 
period.  
 
Implementation was quantified by estimation of MPR per drug and per patient. This 
metric reports medication availability by estimating the proportion of days’ supply 
obtained from community pharmacies during a specified observation period and in this 
thesis it was expressed by: 
 
(a) 𝑀𝑃𝑅 =
number of days′ supply obtained during observation period
number of days in observation period
 x 100 
 
where the observation period refers to the period from index date to 731 days 
afterwards.  
 
Since during the observation period, many changes to the initially prescribed treatment 
occurred, the formula for MPR estimation needed to be adjusted to different situations. 
So, when a new AHT drug was prescribed during the observation period subsequent to 
the index date – in addition to or in substitution of the first drug prescribed – a shorter 
denominator was used (starting from the date of the first dispensing for that new drug): 
 
(𝑏) 𝑀𝑃𝑅 =
number of days′ supply obtained during observation period
number of days between first dispensing date and the end of observation period
 x 100 
 
In the case of additions of new AHT drug(s) to the initially prescribed one(s), no 
changes were made to the formula for MPR estimation of the first drugs. However, in 
the case of substitution or switchingiii, the denominator of the first drug prescribed (and 
that was discontinued) was adjusted as follows:  
 
                                                          
iii We’ve considered substitution or switching in terms of complete discontinuation of one AHT 
drug with initiation of a new drug, regardless when that occurred. 
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(𝑐) 𝑀𝑃𝑅 =
number of days supply obtained during observation period
number of days between first dispensing date and discontinuation date
 x 100 
 
being the discontinuation date, the date of the last dispensing of the initially prescribed 
drug or the index date of the new AHT drug, whichever occurs later.  
 
Figure 3 shows the different scenarios for MPR estimation.    
 
 
Figure 3. Different scenarios for MPR estimation 
In scenario A, MPR is calculated only for a single AHT drug, using formula (a). In scenario B, 
MPR for drug #1 is calculated using formula (a) being formula (b) used for drug #2 (b) – the 
arrow marks the index date for drug #2. In scenario C, MPR for drug #1 is calculated using 
formula (c) being formula (b) used for drug #2 (b) – the arrow marks the index date for drug #2 
and the discontinuation date for drug #1. 
 
For patients receiving multiple AHT drugs, the MPR was estimated for each drug 
separately, and the overall MPR per patient was the mean of the individual MPR values. 
 
Patients were then categorized in three levels of implementation or execution, 
accordingly to their estimated MPR: low (<40%); intermediate ([40-80[%) and high 
(≥80%) implementation. Afterwards, a threshold of 80% was used to dichotomize 
between good implementation and poor implementation (usually expressed in the 
literature as adherent vs non-adherent patients).  
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Calculations of MPR greater than 100% were set to 100%, because even though a MPR 
>100%  may reflect patients refilling prescriptions before the end of their last 
dispensing or hoarding medication for later use, it is unlikely that patients will actually 
use AHT drugs at greater than the prescribed frequency30. 
 
Logistic regression was used to estimate the odds ratio (OR), with 95% CI, for poor 
implementation of the prescribed AHT therapy. Bivariate analysis was conducted to 
determine which characteristics were related to implementation. Categorical variables 
were analysed using chi-square test. The model was adjusted for age, gender, patient’s 
buying power, number of AHT drugs dispensed during follow-up, and number of 
prescribers. 
 
5.4.4. Discontinuation  
 
Discontinuation marks the end of therapy, allowing the estimation of persistence18,25. 
Persistence, like initiation, is a time-to-event variable with a well-defined time origin 
(initiation) and an end-point which is the date of treatment discontinuation25,84.  
 
In this thesis, persistence was considered in terms of therapy persistence84, i.e. the 
proportion of patients remaining on any AHT drug regardless of switching or the use of 
multiple drugs during follow-up.  
 
Starting from index date, all dispensed prescriptions were considered uninterrupted if 
time between the end of one dispensing and the beginning of the following – maximum 
allowed treatment gap or grace period - was lower than 90 days. The discontinuation 
date was set as the end date of the dispensing previous to the first treatment gap of 90 
days or longer. 
 
If the discontinuation date was not observed during the observation period, the patient 
was classified as a continuous user, i.e. persistent. This allowed increasing specificity in 
detecting discontinuers’ or non-persistent patients.  
 
In a second analysis of persistence, we’ve considered just the theoretical end date of the 
last dispensing, regardless the AHT drug and the previous occurrences of treatment 
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gaps, as the discontinuation date. By doing so, we’ve analysed reinitiation of AHT 
therapy115. 
In both situations, persistence to AHT therapy was analysed by Kaplan-Meier survival 
analysis, determining the time to discontinuation for each patient. Patients were 
censored at the end of the follow up.  Estimates of time to discontinuation were assessed 
for the potential predictors of persistence including age, gender, pharmacological class, 
number of drugs during the observation period, number of prescribers during the 
observation period, patient’s buying power, and ICPC-2 code.  
 
Cox proportional hazard regression was used to estimate HR and 95% CI for 
discontinuation, i.e., the proportion of patients not being persistent with treatment after 
two years. The significance threshold was set at 0.05. 
 
Since several studies on adherence to medications have demonstrated that many patients 
interrupt their treatment, shortly after the acquisition in a pharmacy of their first 
prescription11, phenomena called early discontinuation or short persistence29;109, in this 
thesis we’ve also analysed the rate and characteristics related to early discontinuation, 
defined as the fail to ever refill, i.e. a patient acquired only his/her first prescription.  
 
 
5.5. NUMBER OF DAYS’ SUPPLY IN EACH PRESCRIPTION  
 
To determine implementation and discontinuation, we had to consider a number of 
days’ supply obtained in each dispensing, e.g. the duration of a dispensing. Since 
SIARS does not include information about the recommended or individual dosage 
regimen for all prescribed drugs, the (theoretical) duration of a dispensing was 
estimated in consideration to the number of units per package and the standard dosing 
for each AHT drug related to hypertension as a proxy of the prescribed daily dose 
(PDD). 
 
Standard dosing – the maintenance dose, in adults – was retrieved from the SmPC of 
each AHT drug from INFARMED’s (National Authority of Medicines and Health 
Products) website. When the SmPC was not available in Portuguese, EMA’s (European 
Agency of Medicines) website was searched.   
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Since the standard dosing for each AHT drug may vary, we’ve defined it as following:  
- Standard dosing per se (e.g. one tablet per day or one tablet twice a day, with no 
exceptions);  
- In cases of up- or down-titration, if the number of doses is not modified over 
time, it remained unchanged (e.g. ramipril dose can be doubled at interval of two 
to four weeks to progressively achieve target BP; maximum: 10mg daily. 
Usually the dose is administered QD);  
- In cases of dosing range, we’ve considered the lowest dose (e.g. felodipine 5mg 
tablets may be 1 tablet QD or 1 tablet BID; we’ve considered 1 tablet QD to 
increase specificity. 
 
The appropriateness to clinical practice of the standard dosing, as extracted from SmPC, 
was evaluated by a panel of 30 physicians, including general practitioners, cardiologists 
and internists, in a ratio of 4:1:1. We’ve analysed the agreement for the standard dosing 
and the usual prescribing practice of each physician, as well the agreement between 
physicians, using the methodology expressed in Figure 4. Agreement’s analysis was 
conducted using the kappa test. 
 
Figure 4. Flow chart for the analysis of the appropriateness of the defined standard dosing 
 
Only for 3.7% of all dispensed AHT drugs, the defined standard dosing was not 
considered appropriate to clinical practice173. For those cases, and since in all of them 
the drug’s dosing is defined within a dosing range, we’ve defined the standard dosing as 
Agreement between 
extracted standard 










Physicians usual prescribing 
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the lowest dose. By doing so, we’ve increase specificity in implementation and 
discontinuation analysis. 
   
Taking into consideration the number of units per package and the defined standard 
dosing for each AHT drug related to hypertension as a proxy of the PDD, the end date 
of a dispensing equals its start date plus the duration of the dispensing. In case of 




5.6. DATA COLLECTION AND LINKAGE  
 
As mentioned, data was collected from SIARS. In order to preserve privacy, data were 
collected and de-identified using encryption protocols, after which were provided to the 
research team by employees of ARSLVT, according to defined specifications in a 
variables codebook, which was previously discussed with ARSLVT leaders. Therefore, 
we were not be directly involved in data collection.   
 
For each patient, prescription and dispensing/claims data were linked together using the 
unique prescription identification number. However, since each prescription can include 
up to four different drugs and therefore, patients may not acquire all prescribed drugs, 
we’ve also used the ATC code to match both files. Thus, a drug was defined as 
dispensed if there was a match between claims and prescribing records for the 
prescription individual identification number and the ATC code. 
 




5.7. STUDY VARIABLES  
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Table 5. Study variables  
Variables for patient characterization 
Variable Categories (if applicable) Source 
Age continuous (years) 
categorical: 18-44; 45-64; ≥65 
extracted from SIARS 
determined 
Gender male/female extracted from SIARS 
ICPC-2 code k86/k87 extracted from SIARS 
Housing parish code used for determining patients’ buying 
power and Region 
extracted from SIARS 
Buying power categorical: <100;100-199; ≥200 extracted from Pordata  
Region (NUTS III) Great Lisbon, Setubal Peninsula, Middle 
Tagus, West, Leziria West Coast 
determined using patient’s 
housing parish code 
Variables for prescriber characterization 
Variable Categories (if applicable) Source 
Prescriber assigned to 
the patient  
yes/no extracted from SIARS 
Variables for prescription characterization 
Variable Categories (if applicable) Source 
Date of prescription  extracted from SIARS 
(Data per drug): 





Number of packages 
Units per package 
RRP / reference price 
Cost for the NHS 
Cost for patient 
 
ATC code – 5th level 
Diuretics, BBs, CCBs, ACEIs, ARBs, 
Other AHT (ATC code – 2nd level) 
 
 
minimum: 1; maximum: 6 
extracted from SIARS 
 






Legend: SIARS – Information System of the Regional Health Administration; ICPC-2 – 
International Classification of Primary Care, 2nd edition; NUTS – Nomenclatura das Unidades 
Territoriais para Fins Estatísticos; ATC code - Anatomical Therapeutic Chemical code; BBs – 
Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin converting enzyme; 
AHT – Antihypertensive; ARBs – Angiotensin receptor blockers; RRP - Recommended retail 
price; NHS – National Health Service 
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Table 5: Study variables (continuation) 
Variables for prescription characterization 
Variable Categories (if applicable) Source 
Drug classification Single pill/fixed-dose combination determined using ATC 
code 
Duration of prescription 
End date of prescription 
(in days) calculated using date of 
prescription, units per 
package and defined 
standard dosing  
Variables for dispensing characterization 
Variable Categories (if applicable) Source 
Date of dispensing  extracted from SIARS 
(Data per drug): 





Number of packages 
Units per package 
RRP / reference price 
Cost for the NHS 
Cost for patient 
Drug classification 
 
ATC code – 5th level 
Diuretics, BBs, CCBs, ACEIs, ARBs, 
Other AHT (ATC code – 2nd level) 
 
 
minimum: 1; maximum: 6 
extracted from SIARS 
 
determined using ATC 
code 
Duration of dispensing 
End date of dispensing 
(in days) calculated using date of 
dispensing, units per 




PHC sector, Public Hospitals, Private 
practice 
extracted from SIARS 
Legend: ATC code - Anatomical Therapeutic Chemical code; SIARS – Information System of 
the Regional Health Administration; BBs – Beta-blockers; CCBs – Calcium channel blockers; 
ACEIs – Angiotensin converting enzyme; ARBs – Angiotensin receptor blockers; AHT – 
Antihypertensive; RRP - Recommended retail price; NHS – National Health Service; PHC – 
Primary Health Care 
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Table 5: Study variables (continuation) 
Variables for treatment characterization 
Variable Categories (if applicable) Source 
Number of AHT drugs 
prescribed 
continuous  
categorical: 1; 2; 3 or more 
calculated 
Number of AHT drugs 
dispensed 
continuous  
categorical: 1; 2; 3 or more  
calculated 
Initial drug class Diuretics, diuretics combination, BBs, 
CCBs, ACEIs, ACEIs combination, 
ARBs, ARBs combination, Other 
AHT, two or more drug classes 
determined using ATC 
code 
Number of prescribers continuous  
categorical: 1; 2; 3 or more 
calculated 
Variables for adherence characterization 
Variable Formula Source 
Rate of primary 
adherence 
number of claims records / number of 
prescriptions records  
calculated after linkage of 
prescriptions and claims 
records 
Rate of initiation number of new users / total number of 
cohort members  
calculated after linkage of 
prescriptions and claims 
records 
Time to initiation index date – date of index prescription 
(in days)  
calculated after linkage of 
prescriptions and claims 
records 
Rate of early 
discontinuation 
number of early discontinuers / total 
number of new users  
calculated 
Rate of discontinuation  number of discontinuers (non-
persistent) / total number of new users 
calculated 
Time to discontinuation discontinuation date – index date  
(in days) 
calculated 
MPR see section 5.4.3. calculated 
Legend: AHT – Antihypertensive; BBs – Beta-blockers; CCBs – Calcium channel blockers; 
ACEIs – Angiotensin converting enzyme; ARBs – Angiotensin receptor blockers; ATC code - 
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5.8. DATA ANALYSIS  
 
We’ve started by pre-processing raw data provided by ARSLVT in Microsoft Excel 
files in order to check for incomplete data, errors or outliers and discrepancies in codes 
or names. The application of exclusion criteria excluded all patients who didn’t comply 
with criteria set in advance for this study. 
 
From that, we’ve move on to fill in the database with: 
– Time to initiation; 
– Defined standard dosing for each dispensing 
– Duration (in days) and end date of each prescription; 
– Gap between prescriptions (in days); 
– Time to discontinuation; 
– MPR per drug (ATC code – 5th level) and per patient. 
 
This was performed using Microsoft Excel 2013. 
 
These data allowed the characterization of patients concerning to the study outcomes: 
initiation, implementation and discontinuation of AHT therapy. 
 
For baseline description, all patients with index diagnoses and index prescription during 
the first trimester of 2011 were included.  
 
Continuous, e.g., numerical variables were described using standard statistical 
measures: number of observations, mean, standard deviation, median, minimum and 
maximum values. Categorical variables were analysed to determine absolute and 
relative frequencies. When appropriate, to test differences in demographic and other 
characteristics between groups of patients (i.e. adherent and non-adherent or persistent 
and non-persistent), several statistical tests were used (as mentioned in section 5.4.).  
 
The statistical analysis was performed using SPSS, version 23, a level of significance of 
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5.9. DATA PERMIT PROCESS: 
 
This study was approved by the ethics committee of ARSLVT – protocol number 
119/CES/INV2013 and by the Ethics Research Committee of NOVA Medical 
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6.1. PATIENTS’ CHARACTERISTICS  
 
During the first trimester of 2011, 29,896 patients were diagnosed with hypertension – 
ICPC-2 codes k86 and k87 – in the PHC units of Lisbon and Tagus Valley Region. For 
those patients, prescriptions and claims records for AHT drugs were collected from 
SIARS and provided by ARSLVT in two separate Microsoft Excel files, one with the 
prescriptions records for the 29,896 patients and the other with the claims records for 
28,121 of those patients. 
 
Figure 5 shows the flow chart of the application of the exclusion criteria.  
 
29,896 patients diagnosed in the PHC 
units of Lisbon and Tagus Valley 























350 patients <18 years or >90 years old 
29,546 patients aged 18-90 years old  
   
 
  
17,292 patients with at least one 
prescription and/or a claim record in the 
6-months prior to Jan 1st 2011 
12,254 newly diagnosed and treated 
hypertensive patients 
   
 
  
2,050 patients with an index date prior to 
the index prescription 
10,204 newly diagnosed and treated 
hypertensive patients with an index 
prescription prior to the index date     
Figure 5. Flow chart of inclusion and exclusion criteria 
 
After excluding all patients who didn’t comply with the criteria set in advance in the 
prescriptions records file, the same was done in the claims records file, i.e. every patient 
who was excluded from the first file was also excluded from the latter.  
 
After applying the exclusion criteria, prescriptions records file included 68,206 records 
corresponding to 182,841 packages of AHT drugs for the 10,204 newly diagnosed and 
treated hypertensive patients and claims records file included 140,154 records for 9,715 
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patients. Table 6 shows baseline characteristics of patients enrolled in the study, i.e. the 
cohort members.  
 
Table 6. Baseline characteristics of patients enrolled in the study 
Patients’ characteristics men women total 
 4,645 (45.5%) 5,559 (54.5%) 10,204 
Age 
mean (±SD) 
18 to 44 
45 to 64 




































































Legend: SD – Standard deviation; NUTS – Nomenclatura das Unidades Territoriais para Fins 
Estatísticos; ICPC-2 – International Classification for Primary Care, 2nd edition 
a data missing for 9 patients; b data missing for 2,575 patients 
 
The age of the cohort members ranged between 18 and 90 years, with a mean age of 
61.0±13.0 years and a median age of 61.0 years. The mean age of men (45.5% of total) 
was 60.5±12.8 years and of women 61.5±13.2 years. The age difference between gender, 
although small, was statistically significant (p<0.001). 
  
Approximately ¾ (73.9%) of the cohort members were living in the first trimester of 2011 
in the Lisbon Metropolitan Area (LMA), which includes the regions of Great Lisbon and 
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Setubal Peninsula. Although LMA accounts only for about 3.2% of the Portuguese 
territory, it includes 26.5% of the Portuguese population164. Patients from the rural areas 
and the interior (i.e. Middle Tagus, West and Leziria West Coast regions) were older 
(61.3±13.0 years) than patients from the LMA (60.3±13.1 years). This age difference 
between the regions was also statistically significant (p<0.001), reflecting a higher Ageing 
Indexiv of these areas of residence. 
 
Using the patient’s housing parish code, we were also able to determine individual’s 
buying power, extracting that information from the Pordata website (www.pordata.pt). 
Almost one out of three (31.7%) of the cohort members were living in poorer 
municipalities, i.e. with a buying power lower than 100. Patients living in municipalities 
with a higher buying power were older (61.3±13.1 years) than those with a lower buying 
power (60.4±12.9 years). This age difference was also statistically significant (p=0.001). 
 
The large majority (93.3%) of patients were diagnosed by PHC physicians with ICPC-2 
code k86 (hypertension without complications), in spite of differences found considering 
the gender and the age of the patients; k87 diagnosis code was higher among male and 
older patients (p<0.001). However, the actual ICPC-2 code was not provided for every 
patients. In fact, despite our efforts, that specific information was missing for 2,575 
(25.2%) patients. 
 
Worth mentioning is that even though our results reflect incidence of hypertension, they 
are very much consistent with previous findings on the prevalence of hypertension in the 
Portuguese population, including the PHYSA study16 and the PAP study44, where in both 
studies, the authors found that prevalence of hypertension in Portugal increased with 
advancing age, and it was higher in men compared with women in groups aged below 64 




                                                          
iv The Ageing Index correspond to the number of people aged 65 or more per 100 people under 
15 years. A value lower than 100 means that there are fewer elderly people than young people 
(http://www.pordata.pt/Municipios/%C3%8Dndice+de+envelhecimento-458 (5-08-2015) 
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6.2. PRESCRIPTIONS AND CLAIMS RECORDS ANALYSIS  
 
6.2.1. Prescriptions records analysis  
 
As mentioned, prescriptions records are referent only to PHC units. For the cohort 
members, we found that on average, PHC physicians prescribed 3.0±1.0 different AHT 
drugs (in terms of ATC codes – 5th levelv) throughout the two-year observation period for 
each patient (range: 1-10), irrespectively of the new drugs being an addition or a 
substitution to the initially prescribed ones; for each AHT drug, were prescribed 3.0±2.8 
packages, irrespectively of the package size (range: 1-40). 
 
The proportion of patients prescribed with a single AHT drug (ATC code – 5th level) was 
48.5%, slightly higher in men (49.1% vs 48.1% in women), decreasing with age (59.4% 
in the 18-44 age group and 42.3% in the 65 or more group). Younger patients were 
predominantly treated with a single AHT drug (men: 63.1%; women: 56.3%) during the 
observation period and older patients with two or more drugs, irrespectively of the 
occurrence of additions and/or substitutions to the initially prescribed ones (men: 56.2% 
and women: 57.7%) (Figure 6).  
 
 
Figure 6. Number of prescribed AHT drugs, by age group and gender 
 
Overall, agents acting on the Renin-angiotensin system (RAS) (ATC code 2nd level C09), 
in monotherapy or in fixed-dose combinations with other drugs were the most prescribed 
                                                          

























18-44 45-64 65 or more 18-44 45-64 65 or more
men women
1 2 3 or more
 
83 STUDY RESULTS 
AHT drugs throughout the observation period for the cohort members by the PHC 
physicians. Together, ARBs in fixed-dose combinations (24.4%); ACEIs (13.9%); ACEIs 
in fixed-dose combinations (13.9%); and ARBs (13.0%) corresponded to approximately 
two out of three (65%) prescribed AHT drugs. Table 7 presents the distribution of the 
prescribed AHT drugs, by ATC code, 2nd and 3rd levels, throughout the observation 
period. 
 
Table 7. Prescribed AHT drugs during the observation period, by ATC code 
ATC code n (%) total 
n (%) in drug class 
C02 – Antihypertensives:  
C02A – Antiadrenergic agents, centrally acting  




C03 – Diuretics:  
C03B – Low-ceiling diuretics, excl. thiazides  
C03C – High-ceiling diuretics 
C03D - Potassium-sparing agents 






C07 – Beta blocking agents  19,771 (10.8%) 
C08 – Calcium channel blockers 
C08C – Selective CCBs with mainly vascular effects 




C09 - Agents acting on the renin-angiotensin system 
C09A – ACE inhibitors, plain  
C09B - ACE inhibitors, combinations 
C09C – Angiotensin II antagonists, plain  
C09D - Angiotensin II antagonists, combinations 






1,940 (1.6%)  
Total 182,841 
Legend: ATC code – Anatomical Therapeutic Chemical code; CCBs – Calcium channel blockers; 
ACE - Angiotensin converting enzyme. 
 
Fixed-dose combinations, i.e. the combination of one diuretic and one ACEI or ARB or 
the combination of one ACEI or ARB and one CCB, represented 39.7% of all prescribed 
AHT drugs during the observation period. If fixed-dose combinations were counted 
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twice, both in the diuretic or CCBs group and in the ACEIs or ARBs groups, diuretics 
(29.9%), ARBs (27.0%), and ACEIs (20.1%) were the most frequently prescribed AHT 
drug classes by PHC physicians for hypertension treatment for the cohort members.  
 
Considering the prescription by brand or generic name, we’ve found that 54.3% of all 
prescribed AHT drugs throughout the observation period corresponded to brand named 
drugs (from 44.3% in the diuretics class – ATC code C03 – to 96.9% of all 
antihypertensives – ATC code C02), while generic drugs accounted for 45.7% of the 
prescribed drugs (over 50% for diuretics, CCBs, and BBs – 55.7%, 52.3% and 50.8%, 
respectively (Figure 7). 
 
 
Figure 7. Generic and brand named AHT drugs prescribed during the observation period 
Legend: C02 – Antihypertensives; C03 – Diuretics; C07 – Beta blocking agents; C08 - Calcium 
channel blockers; C09 - Agents acting on the renin-angiotensin system 
 
Looking at the AHT drug classes specifically prescribed per patient during the 
observation period, diuretics, alone or in combination with an ACEI or an ARB, were 
prescribed for almost 60% of patients, followed by ARBs (54.0%) and ACEIs (46.4%), 
irrespectively of the number of records for each drug class. Worth mentioning that in this 
analysis of prescribed drug classes per patient, if a patient was initially treated with an 
ARB alone, for example, and later on switched to an ARB in a fixed-dose combination, 


















C02 C03 C07 C08 C09
brand name generic
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Table 8. Proportion of AHT drug classes prescribed per patient, by gender 
AHT drug classes men women total 

























Legend: AHT – Antihypertensive; BBs – Beta-blockers; CCBs – Calcium channel blockers; 
ACEIs – Angiotensin converting enzyme; ARBs – Angiotensin receptor blockers 
 
The differences found in the proportion of AHT drug classes prescribed per patient 
between men and women, were statistically significant (p<0.001) for all classes, except 
for ARBs and the ‘other’ AHT. The proportion of prescribed diuretics, BBs and ARBs 
was higher in women while the proportion of CCBs and ACEIs was higher in men.  
 
Analysing the proportion of prescribed AHT drugs per patient, accordingly to the age 
group, we’ve found that prescription increased with age for diuretics and CCBs, and 
decreased for BBs. In the other drug classes, prescription increased from the 18-44 age 
group to the 45-64 age group and diminish to the 65 or more age group. These differences 
were statistically significant (p<0.001) for all drug classes.  
 
Figure 8 shows the proportion of AHT drug classes prescribed per patient during the 
observation period, according to the age groups.  
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Figure 8. Proportion of AHT drug classes prescribed per patient, by age group 
Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensives  
 
6.2.2. Linkage between prescriptions and claims records for determining primary 
adherence rate 
 
Overall, 107,024 (58.5%) of the 182,841 AHT drugs prescribed by the PHC physicians 
during the observation period were dispensed in a pharmacy, i.e. originated a claim 
record.  
 
The rate of primary adherence increased with age (p<0.001), and it was higher for men 
(p=0.020). 
 
For patients living in the LMA, primary adherence rates were lower than for the rural 
areas and the interior (p<0.001), although, in terms of patient’s buying power, there were 
no differences (in fact, aggregating buying power ≥100, the proportion was 58.5%, the 
same for the lowest buying power) (p=0.788) 
 
Primary adherence rates were also higher for patients diagnosed with ICPC-2 code k86 












18-44 45-64 65 or more
Diuretics BBs CCBs ACEIs ARBs Other AHT
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Table 9. Rate of primary adherence, by patients’ characteristics 
Patients’ characteristics Prescribed drugs Dispensed drugs (%) p-value 












18 to 44 
45 to 64 






















































Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd edition 
a Data missing for 171 prescriptions records; b Data missing for 34,454 prescriptions records 
 
As the literature shows, a good physician-patient relationship improves adherence to 
medications23;148-151. In this primary adherence analysis, we found that the proportion of 
prescribed drugs that were dispensed was slightly higher when the drug was prescribed 
by the patient’s family doctor (58.9% vs 58.1%), although that difference was not 
statistically significant (p=0.117).   
 
Considering the effect of drug classes on primary adherence rates, ARBs, alone or in 
fixed-dose combinations with a diuretic or a CCB, ACEIs in fixed-dose combinations and 
BBs were the drug classes with the highest primary adherence rates, while CCBs and 
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diuretics, alone or in combination with potassium-sparing agents had the lowest rates 
(Table 10).  
 
Table 10. Rate of primary adherence, by drug classes  
 Prescribed drugs Dispensed drugs (primary adherence rate) 















































































Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensive 
 
Both ARBs and ACEIs in fixed-dose combinations had higher primary adherence rates 
compared to their ‘plain’ formulations, in both cases with higher rates for generic drugs.  
Overall, we found no differences in the primary adherence rates of prescribed generic or 
brand name drugs (p=0.710). However, when we analysed each drug class in separate, 
we found statistically significant differences for almost every AHT drug classes 
(p<0.001), except for diuretics in fixed-dose combinations, and the ‘other’ AHT. 
 
Analysing the effect of the out-of-pocket cost for the patients of the prescribed drugs in 
the rate of primary adherence, we’ve found that its increase was associated with a 
decrease in the primary adherence rate (p<0.001), more relevant for diuretics and BBs 
and less relevant for drugs acting on the RAS and CCBs (Figure 9).  
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Figure 9. Effect of out-of-pocket costs in primary adherence rates, by drug classes 
Legend: C02 – Antihypertensives; C03 – Diuretics; C07 – Beta-blockers; C08 – Calcium channel 
blockers; C09 – Agents acting on the renin-angiotensin system 
 
6.2.3. Claims records analysis 
 
Analysing the claims records of AHT drugs dispensed for the cohort members, we found 
that on average, 1.9±2.1 AHT drugs (in terms of ATC codes – 5th level) were dispensed 
per patient during the two-year observation period (range: 1-12), irrespectively of the new 
drugs being an addition or a substitution to the initially prescribed ones; for each AHT 
drug, 3.9±2.8 packages (range: 1-25) were dispensed, irrespectively of the package size. 
 
The large majority (76.4%) of dispensed AHT drugs were originated from PHC 
physicians. Table 11 presents the distribution of all claims records for dispensed AHT 
drugs during the observation period for the cohort members, taking in consideration the 
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Table 11. Distribution of claims records, by healthcare providing system 
ATC Code PHC sector Public Hospitals Private practice 
n (%) total 
n (%) in group 





























































Legend: ATC – Anatomical Therapeutic Chemical; PHC – Primary Healthcare; BBs – Beta-
blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin converting enzyme; ARBs – 
Angiotensin receptor blockers; AHT – Antihypertensive. 
 
Together, ARBs in fixed-dose combinations (23.7%); ACEIs (14.1%); ACEIs in fixed-
dose combinations (13.1%); and ARBs (12.5%) accounted for 63.4% of all dispensed 
AHT drugs.  
 
Still, the proportion of claims by drug classes was not the same when considering the 
healthcare providing system where the prescription was originated from. For ACEIs and 
ARBs, it was higher for prescriptions originated from the PHC sector, compared to public 
hospitals, while for all the other drug classes, it was higher for public hospitals or the 
private sector. These differences were statistically significant (p<0.001), implying 
different prescription patterns for hypertension treatment throughout the healthcare 
system. 
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Since our data indicated a rather low primary adherence rate for AHT drugs prescribed 
by the PHC physicians, we repeated the analysis that we’ve conducted for prescriptions 
records, regarding the proportion of patients being treated with a single AHT drug or a 
combination of two or more drugs, now using the claims records, more close to the actual 
treatment patterns.  
 
The proportion of patients being treated with a single AHT drug was 47.6%, higher in 
men (48.7% vs 46.6% in women), decreasing with age (60.2% in the 18-44 age group and 
41.7% in the 65 or more group). Younger patients were predominately treated with a 
single AHT drug (men: 62.7%; women: 58.1%) during the observation period and older 
patients with two or more drugs, irrespectively of the new drugs being an addition or a 
switch to the initially prescribed ones (men: 57.1% and women: 59.1%) (Figure 10).  
 
 
Figure 10. Number of AHT drugs dispensed per patient, by age group and gender 
 
 
6.3. ADHERENCE MEASURES 
 
6.3.1. Initiation of antihypertensive therapy 
 
Of the 10,204 newly diagnosed and treated hypertensive patients, 8,856 (86.8%) initiated 





























18-44 45-64 65 or more 18-44 45-64 65 or more
men women
1 2 3 or more
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classified as ‘new users’ of AHT therapy. The remaining 1,348 (13.2%) patients were 
classified as ‘non-users’. Characteristics of both groups  are shown in Table 12.  
 
Table 12. Initiation of AHT therapy, by patients’ characteristics 
Patients’ characteristics New users Non-users p-value 










p = 0.226 
Age 
18 to 44 
45 to 64 










































p = 0.007 
Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos;  
a data missing for 9 patients 
 
Male and older patients (65 years or older) shown higher initiation rates, although there 
was no statistically significant difference between gender (p=0.226).  
 
In our study, we’ve also found that there was also no difference in initiation rates between 
regions although patients living in municipalities with a lower buying power had a higher 
initiation rate (p=0.007). 
 
Due to missing data of the actual ICPC-2 code for every patients, we weren’t able to 
analyse the association between the diagnosis code and the initiation of AHT therapy.  
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Like for primary adherence rates, we found no differences in the proportion of patients 
who initiated AHT therapy after being diagnosed and received a prescription by their 
family doctor or by another PHC physician (84.7% vs 85.2%; p=0.622).  
 
Looking at the initially prescribed drug classes, combination therapy of two or more AHT 
drugs – either as a fixed-dose combination or as two or more drugs taken separately - was 
the first choice for 5,427 (52.2%) of the cohort members (Table 13).  
 
Table 13. Initiation of AHT therapy, by drug classes 
Drug classes New users Non-users Total 
Total 8,856 (86.8%) 1,348 (13.2%) n (%) total 




























Single pill / fixed combination 
ACEI – diuretic/CCB 














Combination therapy  







Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensive; ATC code 
- Anatomical Therapeutic Chemical code 
 
Restricting our analysis to patients who initially received a prescription for a single AHT 
drug (ATC code – 5th level), those who initially received a prescription for an ACEI 
and/or an ARB, alone or in a fixed-dose combination with a diuretic or a CCB (single 
pill) had higher initiation rates compared to the other AHT drug classes; initiation rates 
were lower for BBs and CCBs.  
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Worth mentioning, is that for the 1,486 patients who initiated hypertension treatment after 
receiving a prescription of two or more AHT drugs (ATC code – 5th level), 291 (19.6%) 
actually initiated treatment with only a single AHT drug.  
 
Considering the initially prescribed AHT drugs for hypertension treatment of the cohort 
members, including double-counting of fixed-dose combinations, diuretics (45.3%), 
ARBs (44.3%), and ACEIs (36.8%) were the most frequently first prescribed AHT drugs. 
 
An important factor in the decision to initiate hypertension treatment is the out-of-pocket 
cost for the patient. Our results show that when the cost of the initially prescribed drugs 
increased, initiation rates decreased. Patients with co-payments under 5€ were more likely 
to initiate treatment than patients who had to pay over 10€ for the prescribed therapy 
(88.2% vs 83.6%, p <0.001) (Figure 11). Even excluding of patients who were initially 
treated with two or more AHT drugs (therefore with an expected higher cost), the effect 
of out-of-pocket cost remained: increased costs reduces initiation rates (p <0.001). 
 
 
Figure 11. Initiation of AHT therapy, by out-of-pocket cost 
 
To consider the effect of generic or brand name prescribing in the decision to initiate AHT 
therapy, we’ve restricted our analysis for data from patients initially prescribed with a 
single drug, ATC code – 5th level. We found no differences in the proportion of patients 
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6.3.1.1. Time to initiation 
 
For the new users of AHT therapy, the index date occurred 26.4±27.8 days after index 
prescription (median=20.0 days), with differences between men and women: women took 
longer time to initiate therapy (27.0±28.2 days vs 25.8±27.3 days for men) and the gender 
difference increased over time (p=0.024; Figure 12).  
 
 
Figure 12. Kaplan-Meier curve of initiation of AHT therapy, by gender 
Patients diagnosed with hypertension and treated with at least one AHT drug in the PHC units of 
Lisbon and Tagus Valley Region (n=10,204) during the 1st trimester of 2011. Crude estimates. 
 
In spite of the highest proportion of older patients (65 or more years) initiating AHT 
therapy within 6-month after index prescription, time to initiation was lower for younger 
patients and higher for older patients – 45.4 days for the age group 18-44 and 45.5 for the 
age group 65 or more (Figure 13). The differences between age groups were also 
significant (p=0.030).  
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Figure 13. Kaplan-Meier curve of initiation of AHT therapy, by age group 
Patients diagnosed with hypertension and treated with at least one AHT drug in the PHC units of 
Lisbon and Tagus Valley Region (n=10,204) during the 1st trimester of 2011. Crude estimates. 
 
After adjustment for all the potential predictors of time to initiation, the multivariate Cox 
regression analysis demonstrated gender, age, and initially prescribed drugs (in number 
and the drug classes) to be important factors associated with timely initiation of AHT 
therapy. On the other hand, out-of-pocket cost, severity of hypertension (in terms of 
ICPC-2 code) and patient’s buying power had no significant association to initiation after 
adjustments for all potential predictors (Table 14). 
 
The HR for initiation was 6% higher for women (CI: 1.01-1.12), 22% higher for patients 
in the 45-64 age group (CI: 1.17-1.34), 44% higher for patients initially prescribed with 
two or more AHT drugs (ATC code – 5th level) (CI: 1.09-1.89) and was 36% lower for 
BBs, compared to diuretics (CI: 0.44-0.93).   
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Table 14. Factors associated with initiation of AHT therapy 

















18 to 44 
45 to 64 
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Legend: HR – Hazard ratio 
a) calculated with 95% CI; b) Cox regression model including all covariates studied.  
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Finally, as mentioned in section 2.2, non-adherence to medications can manifest itself in 
different ways, one of them being ‘late initiation’29. In this cohort, 855 (8.4%) of non-
users actually initiate AHT therapy although it happened with a considerable delay (time 
to initiation for this patients: 507.2±182.6 days). In fact, during the entire observation 
period, only 493 (4.8%) of the newly diagnosed patients fail to acquire any prescribed 
AHT drugs.  
 
6.3.2. Implementation of antihypertensive therapy 
 
Among the new users of AHT therapy, only 456 (5.1%) patients were classified as having 
a high level of implementation, i.e. MPR≥80% during the two-year observation period. 
For the remaining patients, 3,866 (43.7%), and 4,534 (51.2%) were classified as having 
a low or intermediate level of implementation, respectively.  
 
The proportion of men with a high level of implementation was slightly higher (5.4% in 
men vs 4.9% in women), although that difference was not statistically significant 
(p=0.273).  
 
High adherent patients were predominantly older patients (6.4% of men and 6.6% of 
women). The differences between age groups in the implementation of AHT therapy 
during the two-year observation period were statistically significant (p<0.001). 
 
Figure 14 shows the distribution of patients in three levels of implementation of AHT 
therapy, accordingly to gender and age group.  
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Figure 14. Implementation of AHT therapy, by age group and gender 
 
On average, patients had in their possession, AHT drugs for 43.6±23.1% (in days) of the 
two-year observation period (median 44.0%). Men had in their possession, AHT drugs 
for more days than women (43.8±23.5% vs 43.4±22.8%). However, the MPR difference 
between the gender was not statistically significant (p=0.395). 
 
Dichotomizing patients between good implementation (MPR≥80%, adherent patients) 
and poor implementation (MPR <80%, non-adherent patients), we’ve found that older 
patients (65 years or more) had a 3.9 higher implementation rate of AHT therapy than 
younger patients (18-44 years), being that difference statistically significant (p<0.001).  
 
Although not statistically significant, patients living in poorer municipalities had higher 
implementation rates (p=0.052).  
 
We found no differences in the implementation of AHT therapy, considering the region 
where the patient was from (p=0.331) and the diagnosis code of hypertension (p=0.914). 
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Table 15. Implementation of AHT therapy, by patients’ characteristics 
Patients’ characteristics Adherent Non-adherent p-value 










p = 0.273 
 
Age 
18 to 44 
45 to 64 






















































p = 0.914 
Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd 
a Data missing for 7 patients; b Data missing for 1,228 patients  
 
In terms of drug classes, implementation rates (in terms of MPR) ranged from 42.3% for 
diuretics and potassium-sparing agents in combination to 48.9% for fixed-dose 
combinations of an ARB with a diuretics or a CCB. Like we’ve found for primary 
adherence rates, ARBs and ACEIs in fixed-dose combinations had higher adherence rates 
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Figure 15. Implementation of AHT therapy, by drug classes 
 
For patients who were treated with a single AHT drug (ATC code – 5th levelvi), 205 (4.9%) 
were classified as having a high level of implementation, being that proportion of 5.9% 
(153 patients) and 4.8% (98 patients) for patients treated throughout the observation 
period with two or three or more AHT drugs, respectively. However, these differences 
were not statistically significant (p=0.128). 
 
The number of prescribers involved in hypertension treatment of the cohort members was 
associated with high levels of implementation of AHT therapy: 7.6% of high adherent 
patients who received prescriptions from three of more physicians during the observation 
period vs 3.9% who were followed by a single physician (p<0.001). 
 
The logistic regression analysis confirmed age, number of drugs dispensed during the 
observation period, number of prescribers and patient’s buying power to increase the risk 
of poor implementation of AHT therapy. Gender, ICPC-2 code and initial drug classes, 
had no significant association to low adherence after adjustments for all potential 
predictors (Table 16). 
                                                          
vi In case of substitution of the initially prescribed drug (in which the patient during the 
observation period was actually consuming just one drug at the time) we’ve counted both drugs, 
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Table 16. Factors associated with poor implementation of AHT therapy 

















18 to 44 
45 to 64 
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two 

























































Legend: OR – Odds ratio.  
a Calculated with 95% CI; b Logistic regression model, including all covariates studied 
 
After adjustment, the number of dispensed drugs during the observation period increased 
by 42% (CI:1.09-1.85) the risk of poor implementation of AHT therapy, i.e. non-
adherence. Although not statistically significant, data from the logistic regression model 
shows that higher buying power increases the risk of non-adherence (p=0.054).  
 
6.3.3. Discontinuation of antihypertensive therapy 
 
6.3.3.1. Early discontinuation of antihypertensive therapy  
 
Among the 8,856 new users of AHT therapy, 303 (7.5%) men and 335 (7.0%) women 
completely discontinued their treatment after being dispensed only one prescription, i.e. 
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were classified as early discontinuers. Table 17 shows the differences between early 
discontinuers (non-persistent) and ongoing (persistent) users.  
 
Table 17. Early discontinuation of AHT therapy, by patients’ characteristics 
Patients’ characteristics Persistent Non-persistent p-value 











p = 0.360 
 
Age 
18 to 44 
45 to 64 






















































p = 0.003 
Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd 
a Data missing for 7 patients; b Data missing for 1,228 patients  
 
Younger patients were more likely to early discontinue their treatment (p<0.001). In fact, 
almost one out of five patients under 45 years interrupted their hypertension treatment 
after the first dispensing.  
 
Complications associated to hypertension seemed to have a positive impact on the 
decision to continue treatment: 96.3% of patients diagnosed with ICPC-2 code k87 
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demonstrate an initial engagement with their prescribed treatment, compared to 92.8% of 
patients diagnosed with ICPC-2 code k86 (p=0.003).  
 
Early discontinuation rates were lower in patients living in the West and Leziria West 
Coast regions and higher in patients living in the Middle Tagus and Setubal Peninsula 
regions. These differences were statistically significant (p=0.012). The higher early 
discontinuation rate in patients living in municipalities with a higher buying power was 
not statistically significant. 
 
Again, we found no differences in the proportion of patients who early discontinued their 
hypertension treatment after being diagnosed and receiving a prescription by their family 
doctor or by another PHC physician (7.6% vs 8.5%; p=0.298).  
 
An important aspect to consider in this analysis is that together, ‘non-users’ of AHT 
therapy (i.e. late-initiation or absolute non-initiation) and the early discontinuers, account 
for almost one out of five (19.5%) of the cohort members (n=10,204).  
 
For patients who initiated hypertension treatment with a single AHT drug (in terms of 
ATC code – 5th level), 1,158 (93.1%) and 1,888 (92.4%) who received a combination of 
an ACEI or an ARB, respectively, with a diuretic or a CCB were initially engaged with 
their prescribed treatment.  
 
Higher discontinuation rates were found for patients who initiated AHT therapy with a 
BB or a diuretic, since 405 (89.2%) and 598 (90.3%) patients were initially engaged with 
their prescribed treatment. 
 
Patients initiating AHT therapy with a fixed-dose combination were more likely to 
implement it (at least one more refill) compared to the individual drugs on monotherapy 
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Table 18. Early discontinuation of AHT therapy, by drug classes 
Drug classes Persistent Non-persistent p-value 
Total 8,218 (92.8%) 638 (7.2%)  






















Single pill / fixed combination 
ACEI – diuretic/CCB 










Combination therapy  





Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensive; ATC code 
– Anatomical Therapeutic Chemical code   
 
As for the decision to initiate treatment (previous to adjustment to other factors), higher 
out-of-pocket costs contributed to the decision to early discontinue it (12.5% ≥ 10€ 
compared to 5.7% <5€; p <0.001) (Figure 16). Even excluding patients who were initially 
treated with two or more AHT drugs (therefore with an expected higher cost), the effect 
of out-of-pocket cost remained: increased costs reduces initiation rates (p <0.001). 
 
To consider the effect of generic or brand name dispensing in the decision of initial 
engagement to AHT therapy, we’ve restricted our analysis for data from patients who 
initiated treatment with a single drug, ATC code – 5th level. Again, we found no 
differences in the proportion of patients who early discontinued treatment (generic drugs: 
8.7% vs brand name drugs: 8.4%; p=0.569).  
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Figure 16. Early discontinuation of AHT therapy, by out-of-pocket cost 
 
6.3.3.2. Two-year persistence to antihypertensive therapy  
 
Among the 8,856 new users of AHT therapy, 21.6% of men and 23.1% of women did not 
experience any episode of therapy discontinuation (i.e. grace period longer than 90 days) 
during the first year of hypertension treatment. During the second year, the proportion of 
continuous/persistent users of AHT therapy dropped dramatically to 5.8% in men and 
6.3% in women. The differences between men and women regarding persistence were 
statistically significant (p=0.037). Women had a higher persistence and the gender 
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Figure 17. Persistence to AHT therapy, by gender 
New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus Valley 
Region (n=8,856) during the 1st trimester of 2011. Crude estimates. 
 
We also found differences in the proportion of persistent patients between age groups. 
Only 16 (1.8%) of younger patients (18 to 44 years) were classified as continuous users 
during the observation period while that proportion was 4.5 higher in older patients – 325 
(8.2%) of patients aged 65 years or more were continuous users of AHT therapy during 
the two-year observation period (Figure 18). The differences between age groups was 
found out significant (p<0.001).  
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Figure 18. Persistence to AHT therapy, by age group 
New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus Valley 
Region (n=8,856) during the 1st trimester of 2011. Crude estimates. 
 
Discontinuation rates were lower in the LMA, compared to the rural areas and the interior, 
although that difference was not statistically significant (p=0.129). Still, the higher 
discontinuation rate in patients living in municipalities with a higher buying power was 
statistically significant (p=0.034). Discontinuation rates were also lower for patients 
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Table 19. Two-year persistence to AHT therapy, by patient’s characteristics 
Patient’s characteristics Persistent Non-persistent p-value 










p = 0.300 
 
Age 
18 to 44 
45 to 64 




















































p = 0.001 
Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd 
a Data missing for 7 patients; b Data missing for 1,228 patients  
 
Considering the initially dispensed AHT drug class, 143 (12.0%) of patients who started 
their treatment with two or more AHT drugs were still on treatment two-year after the 
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Table 20. Two-year persistence to AHT therapy, by drug classes 
Drug classes Persistent Non-persistent p-value 
Total 539 (6.1%) 8,317 (93.9%)  






















Single pill / fixed combination 
ACEI – diuretic/CCB 










Combination therapy  





Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensive; ATC code 
- Anatomical Therapeutic Chemical code   
 
For patients who were treated with a single AHT drug (ATC code – 5th level), only 152 
(3.6%) were classified as continuous/persistent users while that proportion was 3.0 higher 
(10.9%) for patients who received prescriptions for three or more AHT drugs (p<0.001). 
Worth mentioning is that this crude estimates are influenced by the fact that persistence 
was considered in terms of therapy persistence, meaning that the number of drugs during 
the observation period was cumulative, irrespectively of the new drugs being an addition 
or a substitution to the initially prescribed ones. 
 
The number of prescribers involved in hypertension treatment of the cohort members was 
also associated with persistence to AHT. 183 (9.8%) of patients who received 
prescriptions for three of more physicians during the observation period had no grace 
period lower than 90 days while that proportion was just 4.5% for patients who received 
prescriptions of AHT drugs from a single physician (p<0.001). 
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The multivariate Cox regression analysis confirmed age, number of drugs dispensed 
during the observation period, and number of prescribers to be important factors 
associated with discontinuation of AHT therapy. Gender, ICPC-2 code, patient’s buying 
power, and initial drug class had no significant association to discontinuation of AHT 
therapy after adjustments for all potential predictors (Table 21).  
 
Table 21. Factors associated with discontinuation of AHT therapy 
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45 to 64 
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one 
two 





































Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd edition; HR – Hazard ratio.  
a Calculated with 95% CI; b Cox regression model, including all covariates studied; c data missing 
for 9 patients 
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Table 21. Factors associated with discontinuation of AHT therapy (continuation) 
























































Legend: HR – Hazard ratio; BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – 
Angiotensin converting enzyme; AHT – Antihypertensive; ARBs – Angiotensin receptor 
blockers;  
a Calculated with 95% CI, b Cox regression model, including all covariates studied.  
 
6.3.4. Discontinuation and reinitiation of antihypertensive therapy  
 
Although only 539 (6.1%) of the new users of AHT therapy we’re classified as continuous 
users, the fact is that the large majority of patients (72.2%) actually reinitiated 
hypertension treatment after the first episode of discontinuation (90 days or longer 
without any AHT drug). This clearly demonstrates the dynamics of the medication 
adherence process, where patients’ frequently stop and reinitiate their treatment.  
 
Figure 19 demonstrates the proportion of persistent patients considering the absence (or 
not) of a grace period longer than 90 days.  
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Figure 19. Persistence to AHT therapy considering the existence of a grace period of 90 
days 
Legend: New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus 
Valley Region (n=8,856) during the 1st trimester of 2011. Crude estimates. The blue line 
corresponds to the proportion of persistent patients taking in consideration only the end date of 
the last dispensing of an AHT drug, regardless the GAPs between dispensings. The green line 
corresponds to the proportion of persistent patients, including in the estimation of persistence 
rates, a grace period between dispensings lower than 90 days.  
 
In this second analysis of persistence (where we included reinitiation of hypertension 
treatment, regardless a previous occurrence of one or more treatment gaps), we found that 
among the 8,856 new users of AHT therapy, 81.4% of men and 83.2% of women were 
still on treatment with at least one AHT drug 1-year after the index date. The proportion 
of patients still on treatment after two years dropped to 70.6% in men and 73.6% in 
women (Figure 20). The differences between men and women regarding persistence were 
statistically significant (p=0.002). Women had a higher persistence and the gender 
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Figure 20. Persistence, including reinitiation, to AHT therapy by gender  
New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus Valley 
Region (n=8,856) during the 1st trimester of 2011. Crude estimates. 
 
We also found differences in the proportion of persistent patients between age groups. 
Less than half (48.5%) of younger patients were no longer on treatment two years after 
initiation, while 79.4% of older patients (65 years or more) still were. In terms of 
discontinuation rates, younger patients had a 2.5 times higher discontinuation rate than 
older patients (Figure 21). The differences between age groups was found out significant 
(p<0.001).  
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Figure 21. Persistence, including reinitiation, to AHT therapy by age group 
New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus Valley 
Region (n=8,856) during the 1st trimester of 2011. Crude estimates. 
 
Discontinuation rates were lower in the LMA, compared to the rural areas and the interior 
(p=0.006). The higher discontinuation rate in patients living in municipalities with a 
higher buying power was not statistically significant. Discontinuation rates were also 
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Table 22. Discontinuation and reinitiation of AHT therapy, by patients’ 
characteristics 
Patients’ characteristics Persistent Non-persistent p-value 










p = 0.002 
 
Age 
18 to 44 
45 to 64 




















































p = 0.012 
Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd 
a Data missing for 7 patients; b Data missing for 1,228 patients  
 
Considering the initially dispensed AHT drug class, 1,497 (73.3%) of patients who started 
their treatment with an ARB in a fixed-dose combination with a diuretic or a CCB were 
still on treatment two-year after the index date, while only 294 (64.8%) of patients who 
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Table 23. Discontinuation and reinitiation of AHT therapy, by drug classes 
Drug classes Persistent Non-persistent p 
Total 6,395 (72.2%) 2,461 (27.8%)  




















39 (39.0%) p<0.001 
Single pill / fixed combination 
ACEI – diuretic/CCB 










Combination therapy  





Legend: BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – Angiotensin 
converting enzyme; ARBs – Angiotensin receptor blockers; AHT – Antihypertensive; ATC code 
- Anatomical Therapeutic Chemical code   
 
For patients who were treated with a single AHT drug (ATC code – 5th level), 1,682 
(39.9%) were no longer in treatment two-year after initiation, while for patients treated 
throughout the observation period with three or more AHT drugs, only 229 (11.2%) 
discontinued completely their hypertension treatment two-year after the index date 
significant (Figure 22). These differences were statistically significant (p<0.001).  
 
 
118 CHAPTER 6 
Figure 22. Persistence, including reinitiation, to AHT therapy considering the number of 
dispensed drugs 
New users of AHT therapy, diagnosed and treated in the PHC units of Lisbon and Tagus Valley 
Region (n=8,856) during the 1st trimester of 2011. Crude estimates. 
 
The number of prescribers involved in hypertension treatment of the cohort members was 
also associated with discontinuation of AHT. Patients who received prescriptions for 
three of more physicians during the observation period had lower discontinuation rates 
than patients who received prescriptions of AHT drugs from a single physician (92.3% 
vs 58.7%; chi-square test, p<0.001). 
 
The multivariate Cox regression analysis confirmed age, region, number of drugs 
dispensed during the observation period, number of prescribers, patient’s buying power, 
and initial drug class to be important factors associated with complete discontinuation of 
therapy. Gender, and ICPC code had no significant association to discontinuation rates 
after adjustments for all potential predictors and therefore were not included in the model 
(Table 24).  
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Table 24. Factors associated with discontinuation, including reinitiation, of AHT 
therapy 
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Legend: NUTS – Nomenclatura das Unidades Territoriais para Fins Estatísticos; ICPC-2 – 
International Classification for Primary Care, 2nd edition; HR – Hazard ratio.  
a Calculated with 95% CI; b Cox regression model, including all covariates studied; c data missing 
for 7 patients; d data missing for 1,228 patients 
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Table 24. Factors associated with discontinuation, including reinitiation, of AHT 
therapy (continuation) 
























































Legend: HR – Hazard ratio; BBs – Beta-blockers; CCBs – Calcium channel blockers; ACEIs – 
Angiotensin converting enzyme; AHT – Antihypertensive; ARBs – Angiotensin receptor 
blockers; a) Calculated with 95% CI, b) Cox regression model, including all covariates studied.  
 
6.3.5. Overview on the medication adherence process   
 
At the end of this chapter, we found that of the 10,204 cohort members, 493 (4.8%) never 
acquired any AHT drug prescribed by a PHC physicians or any other physician and 855 
more (8.4%) initiated hypertension treatment with a considerable delay (six-months or 
longer) after the first prescription.  
 
Among patients with a first dispensing (n=8,856), 638 (7.2%) patients discontinued AHT 
therapy after being acquiring just the first prescription and 519 more (5.9%) completely 
discontinued treatment during the first year, making a total of 1,157 (13.1%) patients who 
were no longer on treatment at the end of the first year. During the second year, 904 
(10.2%) more discontinued AHT therapy.  
 
However, in spite of 6,157 patients were still on treatment two years after the initiation 
of hypertension treatment, only 539 (8.8%) of them were classified as continuous users, 
i.e. had no treatment gap or grace period of 90 days or longer, meaning that the remaining 
5,618 (91.2%) were using AHT therapy in an ‘on and off’ basis, discontinuing and 
reinitiating it over time.  
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Analysing the implementation of hypertension treatment in the two-year observation 
period, among patients with a first dispensing only 456 (5.1%) had in their possession 
AHT drugs for 80% or more days, regardless the occurrence of lapses in implementation, 
i.e. treatment gap or grace periods of 90 days or longer, which occurred in 233 (51.1%) 
of this patients with a high level of implementation. 
 





























In this chapter, starting from an overview of the relationship between non-adherence to 
AHT therapy and lack of BP control in the population, the results of this thesis are 
compared to the published literature on adherence to AHT therapy and put in 
perspective. The novelty of our findings but also this thesis limitations are discussed. 
 
 
ADHERENCE TO ANTIHYPERTENSIVE THERAPY AND BLOOD PRESSURE CONTROL 
 
Hypertension is the most common modifiable CV risk factor, and has been identified as 
the leading risk factor for mortality worldwide1-3. However, and in spite of advances in 
hypertension treatment in the second half of the 20th century, which have provided 
newfound capability for lowering BP in almost every person with hypertension, it 
continues to be a major public health problem whose prevalence is increasing 
worldwide.  
 
Even though the percentage of patients with hypertension that are actually diagnosed 
has increased over time, the percentage of patients with controlled BP has not followed 
the same pattern, despite the therapeutic advances4. In spite of the consequences of 
uncontrolled hypertension being very well known among the general population, the 
vast majority of patients – approximately half to two-thirds4; 57.5% in the Portuguese 
population16 – with hypertension still have inadequately controlled BP.  
 
This means that there is room for improvement in the management of hypertension. 
Although the precise reasons for patients not achieving target BP despite being treated 
are not completely clear yet, still the literature was shown that non-adherence and non-
persistence (discontinuation) of AHT therapy are perhaps the most important causes of 
poor BP control6, which substantiates the importance of this thesis and its findings, 
leaving no doubt about the relevance of concerns about inadequate medication intake. 
 
Thus, assessing adherence to AHT therapy in all of its components and the 
identification of potential risk factors for non-adherence within the Portuguese 
population are of major importance in planning preventive strategies aimed at 
improving BP control and, therefore, modifying the overall CV risk of the population.  
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RELEVANCE OF THIS THESIS  
 
This thesis was conducted on a topic where there is a vast number of publications. 
However, there is also a wide range of terms used to define the act of acquiring 
prescribed medications and taking those prescribed medications appropriately. All this 
terms describe a deviant behaviour and are often used interchangeably, although 
defining different aspects of the medication-taking behaviour25,105. Even the 
methodological aspects vary immensely. For example, in the absence of any gold 
standard, Hess et al160 identified 11 different methods for calculating adherence using 
pharmacy administrative databases.  
 
Thus, the wide range of adherence and persistence (or discontinuation) rates in 
published studies is presumably a reflection not only of the number and complexity of 
reasons for deviant medication-taking behaviour18 but also of the range of 
methodologies and AHT drugs that have been used in the conducted studies.  
 
So, in this thesis we’ve considered the definition of adherence to medications as has 
been proposed by ABC Project: “the process by which patients take their medications as 
prescribed”77. As a (dynamic) process it consists of three components: initiation, 
implementation and discontinuation. The main implication of this definition is that 
adherence is not a therapeutic parameter that can be described by a single number, as 
usually reported in the literature.  
 
However, quantification of adherence and interventions to its improvement have been 
largely conditional on patients acquiring their initial prescriptions, and have failed to 
accurately account for the component of initiation. 
 
In a scoping review180 we’ve conducted during December 2014 aiming to describe the 
scope (quantity, focus and nature) of published research on medication adherence in the 
Portuguese population, we found a lack of publications on initiation and discontinuation 
of hypertension treatment. We also found in that review that with the exception of the 
study published by Moita et al42, all studies evaluated adherence at a local level, with 
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small samples of patients (range: 61 to 197 patients), therefore limiting the extrapolation 
of their results to the Portuguese population.   
 
Additionally to the study conducted by Moita et al42 aiming to characterize the 
adherence behaviour to ARBs of hypertensive patients living in Alentejo, one other 
study was recently published where primary (non-)adherence was evaluated in the 
Portuguese population (a cross-sectional study undertaken in the community pharmacies 
of the LMA between March and April 2012)41. In both studies, primary adherence was 
defined as the ratio between dispensed and prescribed drugs, not differentiating between 
newly treated patients and ongoing/established users of AHT therapy. 
 
Although sometimes used in the literature interchangeably, primary adherence and 
initiation are not necessarily synonyms, and so we’ve evaluated both aspects of the 
medication-taking behaviour, which was an innovate feature of this thesis.   
 
In this context, and to the best of our knowledge, this was the first study in Portugal to 
determine adherence including the three components of the adherence process – 
initiation, implementation and discontinuation/persistence – for AHT therapy. All 
previous studies, with the aforementioned exceptions41-42, focused only in the 
implementation component, by analysing adherence within ongoing/established users35-
40.  
 
This was also an innovative feature of this thesis because the determinants of adherence 
are not the same for initiation, implementation and discontinuation. For example, our 
results show that in spite of men demonstrated higher initiation and implementation 
rates than women, women demonstrated higher persistence than men. Not all of this 
findings were statistically significant, but they demonstrate that the same risk factor 
may influence adherence in a different manner overtime.  
 
We also have to consider that one patient’s determinants of adherence can change over 
time, for example, the beliefs of the patient concerning his/her disease and his/her trust 
in the therapy can evolve25;128. Thus, the prediction of non-adherence for individual 
patients is therefore difficult. That’s why measurements of the three elements of 
adherence are required to established multifaceted interventions to improve adherence. 
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Also, an innovative feature of our thesis was the use of prescriptions and 
dispensing/claims records for quantification of adherence to the wide array of AHT 
drugs. The study conducted by Moita et al42 evaluated only to ARBs and all the other 
studies on adherence to AHT therapy in Portugal were cross-sectional (therefore, not 
allowing estimation of how long medications are used) and evaluated adherence using 
questionnaires as the main source of information35-41, a more prone to error method, 
easily distorted by patients23,25. 
 
 
ADHERENCE TO ANTIHYPERTENSIVE THERAPY IN THE LISBON AND TAGUS VALLEY 
REGION: MAIN FINDINGS 
 
The results of this thesis confirm previous observations62-63,66,86,91-92,115 that in clinical 
practice hypertension treatment is frequently abandoned and poorly implemented over 
time.  
 
In this population, almost one out of five (19.5%) patients either never initiated 
treatment, did it with a considerable delay (after six months or more after receiving a 
first prescription for at least one AHT drug) or completely discontinued it just after 
acquiring their first prescription. Overall, only 539 (8.8%) of patients that were still on 
treatment two years after initiating hypertension treatment, were classified as 
continuous users, i.e. had no episode of discontinuation. The remaining patients either 
completely discontinued their treatment or implemented it on a ‘on and off’ basis, 
which was reflected on a very low proportion of patients (5.1%) classified as having a 
high level of implementation. 
 
We found that the risk of completely discontinuing all AHT therapy was most 
pronounced during the first year, which is consistent with other studies 
findings28,91,95,115, where it has been demonstrated that discontinuation rates are likely to 
be higher during the first year of follow-up but are more likely to remain rather stable 




Possible reasons might have been uncertainty about whether or not real hypertension 
existed and the appearance of adverse drug effects. In fact, the literature shows that sub 
optimal adherence is partly due to the asymptomatic nature of hypertension56,67,128,130. 
Due to that fact, during hypertension treatment patients may experience no symptom 
relief and experience more side-effects while taking their medications correctly. The use 
of diuretics was associated with one of the lowest primary adherence rates and also with 
complete discontinuation and of AHT therapy, just like BBs (only drug class, not 
considering the ‘other’ AHT class, with an early discontinuation rate over 10%), which 
were possibly due to increased adverse effects of drugs from this drug classes, as found 
by other authors107,128. 
 
Overall, and concerning the impact of drug class on adherence to AHT drugs, our 
results are consistent with the meta-analysis conducted by Kronish et al19, where the 
authors demonstrated superior adherence to ARBs and ACEIs and inferior adherence to 
diuretics. ARBs seem to be associated with placebo-like tolerability175, with lower 
adverse effects reported compared to other AHT drug classes50. 
 
However, it is a matter of concern if many patients needing AHT therapy stop their 
treatment during the first months after treatment initiation. In our study, persistence (not 
considering treatment reinitiation) was lower compared with other studies59,93-95,121. In a 
general practice study in the UK, one in two patients had discontinued all AHT therapy 
by 3 years post-treatment initiation95. In a Sweden study using medical records for 
patients with hypertension in 48 Swedish PHC centres, persistence after two years was 
65%121 and in a German study persistence after four years ranged from 27% for 
diuretics to 34% to CCBs94. In a Norwegian study analysing persistence after four years, 
two-thirds of the initial users of thiazides and ARBs were persistent users after four 
years59.  
 
However, in those studies, the definition of persistence is not the same. Still, as 
persistence dissimilarities between countries are pronounced, it is unlikely that they are 
due to different definitions alone. In this thesis, low persistence rates with AHT therapy 
and the differences must lead us to pay some attention to the functioning of our 
healthcare system. In fact, we cannot rule out the possibility that patients may acquire 
AHT drugs in a community pharmacy without a medical prescription. Although all 
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AHT drugs are classified as ‘prescription required’, it is known that patients sometimes 
acquire them without a prescription. A study published in the June 2015 journal of the 
Portuguese consumers association (DECO Proteste) shown that 14% of the study 
responders had already bought a drug classified as ‘prescription required’ in a 
pharmacy. Therefore that may imply that we’ve had overestimate not just 
discontinuation rates but also the implementation of AHT therapy. 
 
On this matter, in this thesis we found a higher risk of complete discontinuation of AHT 
therapy, even taking in consideration a possible reinitiation over time, for patients with 
the highest buying power (HR=1.60; CI: 1.33-1.92). This finding might be a 
consequence of patients acquiring AHT drugs without a medical prescription. In this 
case, patients with a higher buying power could more easily afford to pay the RRP of 
the drug than patients with a lower buying power, therefore, having to require a 
prescription for the family doctor or other physician to acquire AHT drugs. Further 
research will be needed to demonstrate exactly how much AHT drugs are dispensed in 
pharmacies without a prescription.  
 
Our results also show that younger patients were more likely to completely discontinue 
their treatment, after the first dispensing or during the two-year observation period. In 
fact, almost one out of five patients under 45 years interrupted their hypertension 
treatment after the first dispensing. Different factors may play a role in this decision: as 
we already mentioned, it’s well known that the asymptomatic nature of hypertension 
reduces patient motivation to take the drugs as prescribed56,67,128,130, which might be 
more relevant for younger patients; also this patients may adhere to appropriate lifestyle 
changes that have a positive impact on the evolution of the disease and therefore, reduce 
the need of medications. Finally, early and long term discontinuation can reflect adverse 
events of AHT drugs. In fact, the study conducted by Cabral e Silva82 demonstrated that 
the main reasons for non-adherence related to the drugs themselves were adverse events 
and symptomatic improvement followed by discontinuation. 
 
Looking to the primary adherence rate of AHT drugs prescribed by PHC physicians, we 
found that 41.5% of all prescribed AHT drugs were not purchased by the patients. 
Overall, the rate of primary adherence we’ve calculated reflects what already was 
known from studies conducted in other population-based studies using pharmacy refill 
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rates: patients typically obtain less medication than they have been prescribed30,42,75. 
Restricting the analysis to ARBs, the rate of primary adherence was much similar to the 
rate calculated by Moita et al42 to ARBs in the Alentejo Health Region in the years 
2010-2011, using the same methodology, which was 61.2%.  
 
Even if we didn’t account for all prescribed packages and counted every prescription 
record as a single package the primary adherence rate would be 69.7%. Still, that would 
mean that over 30% of all prescribed drugs were not acquired by patients.  
 
Thus, our results present a considerably lower primary adherence rate (or a higher 
primary non-adherence rate) compared to other studies. Fischer et al102 evaluated 
195,930 e-prescriptions for different drug classes and for AHT drugs found a primary 
non-adherence rate of 19.5% for AHT drugs. Ax and Ekedahl174 evaluated 44,607 e-
prescriptions in a Swedish population and found a non-adherence rate of just 2.5%. 
Karter et al108 identified 5% primary non-adherence, and Raebel et al113 7%. Cooke112 
found that 15.6% of new prescriptions for AHT drugs were never acquired by patients. 
Shah et al103 found that 17% of prescriptions that were written for AHT drugs were 
never purchased at community pharmacies. 
 
However, studies conducted in Portugal regarding primary (non-)adherence reflect 
much similar rates to our ones. For example, the study conducted by Moita et al42 
revealed that primary adherence stood at 61.2%. Costa et al41, in the previously 
mentioned cross-sectional study undertaken in the LMA identified 22.8% of patients as 
non-adherent. However, data was collected from patients that actually went to the 
pharmacy and didn’t acquire all prescribed drugs, which in the literature has been called 
abandoned prescriptions107,174. This means that were also other prescriptions written by 
the physicians that were not delivered to the pharmacy, which may indicate a sub 
estimation of primary non-adherence. 
 
Medication-taking behaviour is extremely complex and individual, and influenced by 
multiple factors; no less than 771 individual risk factor items were identified as being 
associated with adherence to long term treatment128.  
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Numerous studies56;65-66,102,110-112,131-132 found that increased out-of-pocket costs are 
associated with decreased use of prescribed medications, even for highly effective ones, 
such as AHT, which was also found in this thesis not just for primary adherence rate, 
but also for treatment initiation and early discontinuation.  
 
However, and as we’ve described in chapter two, the higher rate of adherence to ARBs 
compared with diuretics, for example, suggests that drug cost plays a relatively minor 
role in AHT adherence. Actually, when adjusted with other potential risk factors for 
initiation, we found no statistically significant association between out-of-pocket cost 
and initiation of AHT therapy.  
 
Moreover, we found no differences in the primary adherence rates of prescribed generic 
or brand name drugs (p=0.710). Also, there were no differences on the rate of initiation 
and on the rate of early discontinuation between generic and brand name drugs (86.1% 
vs 85.6; p=0.497 and 8.7% vs 8.4%; p=0.569, respectively). The availability of generic 
forms of most AHT drugs seems to mitigate the impact of out-of-pocket cost on 
adherence, as demonstrated by other authors103;107. This finding is also in line to 
previous studies107,133,182 on the impact of generic AHT drugs on medication adherence. 
 
Also, our findings support the fact that the use of low-dose combinations favours 
adherence probably because of the smaller side effects compared to full-dose 
therapy5,63,138, and also because it reduces the complexity of therapy.  
 
Unmeasured patient and physician factors, such as the extent of physician–patient 
communication and education about prescriptions are likely to influence adherence, as 
shown in the literature. Still, in this thesis, we’ve found slightly higher primary 
adherence rates when the drug was prescribed by the patient’s family doctor, although 
such differences were not statically significant. Also, initiation and early 
discontinuation rates were not influenced by that fact, implying that in this population 
that is not an important risk factor for non-adherence.  
 
Although individuals at low socioeconomic status have sometimes been reported to 
have a lower adherence to treatment11,67,128,130,181, in this thesis, patients with higher 
buying power demonstrated higher discontinuation rates, just like in the study 
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conducted by Corrao et al62 in the Lombardy (Italy) population. However, those 
differences were not statistically significant for early discontinuation (p=0.439), and 
after adjustment to other predictors of discontinuation, it was associated with 
discontinuation of AHT therapy (p=0.696) meaning that in the Lisbon and Tagus Valley 
population, implementation and/or discontinuation of AHT therapy is not related to the 
socioeconomic status. However, and as we’ve mentioned, if we account for reinitiation 
in the definition of persistence, higher buying power increased the risk of 





While trying to assess the clinical relevance of inadequate medication-taking behaviour, 
we have to consider several aspects of non-adherence with chronic medication. Without 
doubt, non-adherence with any form of chronic treatment generally means less 
protection against worsening of symptoms or protection against the occurrence of 
complications.  
 
However, this raises a question often posed when it comes to adherence namely “how 
much adherence is enough?” There is no mutual agreement among health care 
professionals about what adequate adherence is. As we’ve mentioned, a ratio of 80% is 
often accepted as cut-off value between adherent and non-adherent in AHT treatment 
research. Several studies, carried out in PHC settings and using medication records for 
adherence calculations, in which the effect of non-adherence on clinical outcomes was 
investigated, have demonstrated that an adherence level of approximately 80% may 
already be sufficient for a satisfying BP62-64,176.  
 
For some drugs with a long half-life or with extended release formulations, missing a 
dose may be less clinically relevant (forgiving drugs), although non-adherence still 
reflects unwanted behaviour178-179. From a pharmacological point of view, we could 
even argue that missing one dose will have limited or no pharmacodynamics 
consequences. It is, in fact, the plasma half-life of AHT drugs that determines whether a 
pharmacodynamic effect persists when a patient misses a single dose. Despite these 
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considerations, it remains difficult to define an adherence level that is absolutely 
necessary for reaching adequate BP reduction.  
 
Nevertheless, it seems obvious that allowing a patient missing a dose now and then or 
even allowing longer periods of missing doses (i.e. drug holidays), is acceptable if it 
means that the patient is prepared to continue the use for years. Missing one or perhaps 
even a few doses may have no demonstrable effect on outcome. As Corrao et al62 have 
demonstrated, not just an optimal (80% or more of doses), but even a suboptimal or 
partial adherence to AHT therapy may offer significant advantages, compared with an 
extremely low adherence (less than 40% of doses).    
 
In case of individual AHT drugs or even AHT drug classes, it is impossible to even 
suggest an overall cut-off value for clinically relevant non-adherence. However, if 
rebound effects are absent or unlikely to occur, it seems irrelevant to strive for 
perfection and in this light 80% seems an acceptable limit. In addition, this cut-off value 
can also be recommended in new studies, because it enables comparison between 
studies and is the most frequently used cut-off value in pharmacoepidemiology26.  
 
Also important to consider is the fact that MPR is the accepted standard for the 
evaluation of adherence using retrospective data26,34,105: it is easy to calculate, and is the 
most commonly used metric, allowing for comparisons among studies. MPR is the best 
available measure for assessing adherence to AHT therapy using retrospective data34,105. 
 
Another problem addressed in this thesis is the definition of persistence. We already 
addressed the problem of defining adherence with regard to the frequently used cut-off 
value of 80%. The same problem may be encountered with regard to non-persistence. A 
large number of studies on persistence with AHT drugs have been performed using 
different definitions. When studying persistence, instead of defining a cut-off value, 
which is the case with adherence, we have to define when a gap between two 
prescriptions is so large that continuous use can no longer be assumed. Therefore, 
setting the cut-off for that maximum medication gap is equivalent to define the 
sensitivity of the measure because the smaller the allowable gap, the higher the number 
of patients classified as having discontinued or being non-persistent. A 90-day gap 
might be adequate to detect true non-persistence because a study investigating the 
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impact of several gap selections on persistence observed no major change with 




LIMITATIONS OF THIS THESIS 
 
Naturally, this has a number of potential limitations, most of them related to the method 
used for estimating adherence to AHT therapy, i.e. the use of medication records, 
namely an electronic prescriptions database as well a pharmacy dispensing/claims 
database.  
 
The use of medication records is the most feasible and widely used source of 
information to estimate adherence in large populations26,84,105. Additionally prescription 
and dispensing/claims (refill) databases have been considered the gold standard method 
for initiation measurement if both databases are combined118, which as we’ve 
demonstrated can be done within SIARS, and also for discontinuation, with the 
limitation of being retrospective. 
 
Medication records are increasingly collected worldwide and available from different 
sources such as prescribing, dispensing, or reimbursement databases. The ready 
availability of these records has stimulated widespread use of these data to study 
patterns of medication use and assess medication adherence in daily clinical 
practices31,33,105. Calculations with medications records represent a simples approach to 
determine how much of the prescribed medications are being taken (i.e. adherence) and 
for how long (i.e. persistence). They are objective, non-invasive, and economical for use 
in large populations because they can be easily derived from data routinely collected for 
administrative or other purposes, such as the case of SIARS.  
 
In fact, the construct of medication adherence comprises a set of inter-related health 
behaviours. One of such behaviours, the act of acquiring a prescribed medication, can 
be estimated objectively using electronic databases such as pharmacy dispensing and/or 
claims databases101.  
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Over the last years, advances in electronic prescribing have expanded the ability to 
assess whether or not patients obtain their initial prescriptions, the first component of 
the medication adherence process25,101. As we’ve demonstrated with our results, 
electronic prescribing allowed the possibility to identify cohorts of patients who have 
been prescribed new drugs and determine whether those drugs were ever dispensed, 
were acquired only once or more, were used as prescribed, or subsequently discontinued 
without clinical advice or recognition108. 
 
However, while using medication records for estimation of adherence to medications, 
some assumptions have to be made. 
 
First of all, we have to assume that medication records are complete, comprehensive, 
and accurate. In our case, although data collected from SIARS have not been subject to 
previous validation, the drug claims database is a highly accurate data source because 
community pharmacies have to submit error free claims for reimbursement of the 
government funded components of dispensed drugs, otherwise they won’t receive that 
reimbursement.  
 
Secondly, the assumption that the first intake occurred on the day of the first 
acquisition, which may not be case. Also, the assumption has to be made that the 
theoretical duration of an individual dispensed drug corresponds to the actual drug use, 
i.e. the medication is taken as indicated, which may also not be invariably the case. This 
means that dispensing/claims records were used as a proxy for actual medication taking 
process, even though a prescription acquisition is not equivalent to ingestion of the 
drug. However, it can be reasonable assumed that patients would not continue to refill a 
prescription without the intention to adhere. 
 
Other assumptions underlying adherence measures with medication records include (i) 
lack of a refill equals a medication not consumed after the oversupply is exhausted, i.e. 
medication has been discontinued; (ii) medications are not purchased or borrowed from 
another person or venue and finally, (iii) no unknown treatment interruptions or dosing 




By assuming that lack of a refill equals a medication not being consumed, a patient may 
be classified as a discontinuous user because he was advised to do so by the physician 
for different reasons – even though that’s not typical in hypertension treatment. In fact, 
the use of medication records does not make it possible to determine whether 
discontinuation was prescriber-initiated or patient-initiated or even if the patient 
obtained his medication from sources not captured in the available data, such as sharing 
medication with others, like family members, and/or obtaining medication directly from 
a pharmacy, without a prescription. That’s why we have to assume that medications are 
not purchased or borrowed from another person or venue. In this situations, non-
adherence and/or non-persistence may be overestimate.  
 
As we’ve previously demonstrated in this chapter, in our country, AHT drugs can be 
acquired in a community pharmacy without a medical prescription. The Pharmaceutical 
Good Practices for community pharmacy183 include the possibility of an emergency 
dispensing depending on the evaluation and dispensing of a medication that a patient 
requires in emergency conditions, which requires previous knowledge of the patient’s 
pharmacotherapeutic profile. In this conditions, the dispensing does not match to a 
claim and, therefore, that information in not recorded in SIARS, which may 
overestimate non-adherence and non-persistence.  
  
Other limitation of this thesis is that prescriptions records lack the indication for which 
AHT drugs were prescribed. With AHT drugs, there may be some uncertainty on the 
indication because they can also be prescribed for other medical conditions, such as 
angina pectoris, heart failure, cardiac arrhythmias, and other CV diseases. This could 
introduce several forms of bias. In studies like this, a relevant number of patients, who 
do not use AHT drugs for hypertension, can incorrectly be classified as non-adherent or 
non-persistence. This could lead again to an overestimation of the problem of non-
persistence or non-adherence. To control for that, our cohort included only patients with 
prescription of AHT drugs and diagnosis of hypertension, expressed in k86 and k87 
ICPC-2 codes. Still, we couldn’t control for all patients’ characteristics that may 
influence the drug choice.  
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However, different studies in multiple European countries have demonstrated that the 
majority (up to 80%) of AHT drugs prescriptions were indeed prescribed for 
hypertension related diagnoses59,62,182.  
 
Also, in this thesis, the six-month run-in period1 in which we’ve identified prescriptions 
and/or claims records of AHT drugs (excluding those patients from the cohort) also 
allowed us reducing indication bias associated with the prescription of an AHT drug for 
other indications, even in the case of an actual hypertension diagnoses during the first 
trimester of 2011. 
 
Also to consider, the absence of data on possible confounding factors, such as co-
morbidities, actual socioeconomic status (and not just patient’s buying power), severity 
of concomitant diseases, and other risk factors for CV diseases, might be a limitation in 
the evaluation of adherence to AHT treatment.  
 
Another limitation concerns the lack of information on dosage regimen in the database. 
Relaying on days’ supply information for estimation of MPR and also time to 
discontinuation imply that information on that should be as accurate as possible. SIARS 
do not provide information on days supplied for prescriptions but do include amount 
dispensed. Therefore the number of days supplied was determined by defining a 
standard dosing for each AHT drug and evaluating its appropriateness to clinical 
practice using a panel of clinicians from different specialties.  
 
We found that the defined standard dosing was appropriate for 96.3% of AHT drugs, 
with highest agreement for drugs whose standard dosing was QD, and when where 
prescribed by a PHC physician.  
 
For this thesis, we decided not to use the defined daily dose (DDD) for the calculation 
of the number of days supplied within each dispensing, since it does not necessarily 
reflect the recommended or PDD in AHT drug classes158. Therefore, using DDD in 
medication adherence studies may introduce misclassifications159 because it may differ 
                                                          
1 This six-month run-in period is recommended by Halpern84 and it is commonly used in 
adherence studies analyzing new users of AHT therapy34,63,65,102,139,184. 
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from the PDD of an individual patient, thus not reflecting its use in “real world”158-159. 
Defining a daily dose per drug and not per ATC code/active substance, as we’ve done 
allowed a more reliable estimation of adherence to medications using prescription 
and/or claims records. 
 
Finally, and as Karter et al108 pointed out, claims-based research is subject to 
misclassification because all prescriptions not captured in the claims database are 
considered not dispensed, yet there are other reasons for not capturing dispensings, such 
as system failure or malfunction of the prescribing software or still an accidental drug 
entry prescription by the physician during the consultation; another reason may be that 
in spite of the fact that it isn’t highly common, some AHT drugs may be prescribed as 
needed and therefore, not dispensed by the patient at the pharmacy. Therefore primary 
non-adherence may be overestimated. 
 
In spite of this limitations, the use of rates of prescription refills is an objective method 
to calculate both adherence (in its various components) and persistence with chronic 
therapy, which requires a closed pharmacy system – just like the one existing in our 
country, to improve its reliability.  
 
Also, databases such as the ones we’ve used for this thesis provide an estimate of the 
highest possible level of medication possession and, thus, can identify those patients not 
able to consume the medication in sufficient quantity. In that sense, the measures can be 
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CONCLUSIONS 
 
The main objective of this thesis was to determine adherence to AHT therapy in newly 
treated hypertensive patients in PHC units from Lisbon and Tagus Valley Health 
Region, in its three components – initiation, implementation and discontinuation.  
 
Our results demonstrated some relevant findings. The first, is that almost one out of five 
(19.5%) patients either never initiated treatment, did it with a considerable delay (after 
six months or more after receiving a first prescription for at least one AHT drug) or 
completely discontinued it just after acquiring their first prescription.  
 
A second relevant finding is that over a quarter of patients that actually initiated 
hypertension treatment completely discontinued it by the end of the second year.  
 
A third important finding is that the large majority of patients implemented 
hypertension therapy on a ‘on and off’ basis, i.e. discontinuing (for a minimum period 
of 90) and then reinitiating it. This means that the decision to discontinue hypertension 
treatment is not definitive and therefore physicians should actively try to monitor 
adherence and discussing it with patients trying to identify restraints for the continuous 
use of the prescribed medications. Naturally, the effect of these types of interventions 
needs to be established in further studies.  
 
Finally, a fourth finding of this thesis is that overall, almost one out of two prescribed 
AHT drugs were not dispensed (overall primary non-adherence rate = 41.5%), which 
was reflected in an average MPR of 43.6±23.1% (median 44.0%).  
 
All of this findings combined, imply that the potential benefits of AHT therapy in 
lowering CV risk and the consequences of uncontrolled hypertension, cannot be fully 
realized in this population. Thus, the low adherence rates to AHT therapy, in all its 
components, is an especially alarming finding, since hypertension contributes greatly to 
the burden of mortality and morbidity from CV disease in Portugal.  
 
Previous studies on adherence to AHT therapy in Portugal demonstrated higher 
adherence rates, compared to the ones found in this thesis. However, it is known that the 
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use of questionnaires and interviews to patients tend to overestimate adherence. Thus, 
our findings show a more clear landscape of the reality of adherence to AHT therapy in 
newly diagnosed and treated patients. 
  
It has also previously been shown that in our country, many patients with hypertension 
either lack awareness of their diagnoses or are not receiving treatment16. Our findings 
demonstrated that even for patients receiving treatment, they either discontinue or 
poorly implement it over time. 
 
So, non-adherence, in all its manifestations, translates into lack of BP control, which 
will ultimately also increase patients’ risk of CV and related sequels and may lead 
physicians to assume inadequate effectiveness of the medication(s) being used and 
therefore adding or switching AHT drugs to hypertension treatment. As Cramer69 
pointed out, physicians should operate under the assumption that patients take 
approximately half of medications as prescribed, and therefore should look for non-
adherence, as a reason for ineffectiveness of a treatment.   
 
For all of this reasons, it has been suggested that increasing the effectiveness of methods 
for improving adherence may have a far greater positive impact on human health and its 
economics than any single improvement in medical treatment. 
 
In that context, our results, may be instrumental for the development of interventions 
that encourage patients to initiate and use medications as prescribed, in a mutual 
agreement with the physician, leading to a full course of chronic therapy. Naturally, 
further research will be needed to confirm and better understand the causes of these 
findings and to develop interventions to improve adherence to AHT therapy, especially 
by the evaluation of other known risk factors unmeasured within this thesis and 
focusing on the individual patient’s behavioural intentions, barriers and subjective 
norms. Since only a small fraction of the hypertensive population has an elevation of BP 
alone, with the majority exhibiting additional CV risk factors6, adherence to AHT 
therapy should looked at by considering other drugs that the patients may be taking.   
 
The medication-taking behaviour is extremely complex and influenced by hundreds of 
different determinants17. Determinants of non-adherence to AHT therapy such as the 
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long duration of therapy, symptomless nature of the disease, and medication related 
issues don’t represent the full extent of risk factors for non-adherence. That’s why 
further research must complement this population-based analysis with patient’s 
perceptions about the disease and its treatment and patient’s motivation and beliefs. 
 
Also to considerer, the need to address the effect of lifestyle changes on BP control. The 
lowest implementation and discontinuations rates we found in this thesis for younger 
patients may be a result of the biasing effect of such changes, which are registered in 
databases like SIARS and therefore, may have confounded this study. In future 
observational studies, evaluation of lifestyle changes in a small subset of the population 
can help to estimate and adjust for the residual confounding resulting from the lack of 
information in SIARS. 
 
Still, we have to consider that the literature shows that interventions aiming to improve 
adherence to AHT therapy have not demonstrated to be consistently effective in that 
intention8,67. Therefore interventions aimed at improving BP control must address the 
needs and challenges of patients in the various elements of the adherence process, 
especially for those who are first initiated on their prescribed drugs.  
 
Overall, our results support the use of generic drugs and fixed-dose combinations for 
hypertension treatment. Also, our results reflect higher adherence rates for drugs acting 
on the RAS, compared to other AHT drug classes.  
 
Finally, the benefits of using medication records not just for adherence evaluation but 
also to evaluate the effectiveness of interventions to improve adherence, cannot be 
ignored. These records results in better data sources and opportunities for real-time 
monitoring. Until recently, most of the evidence on medication adherence was based on 
follow-up studies of patients who have acquired their first prescription, underestimating 
the public health burden of poor medication adherence for newly prescribed drugs. 
 
In our country, since 2010 electronic prescribing is mandatory for all NHS reimbursed 
drugs. This creates an electronic record of the written prescription, and so its use 
provides an opportunity to determine primary non-adherence of prescribed drugs, as 
well the rate of initiation of newly diagnosed and treated patients. Linking prescriptions 
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records to claims records also allowed determining whether AHT drugs were dispensed 
just once (early discontinuation), used as prescribed (implementation), or subsequently 
discontinued, therefore creating to measure adherence and persistence in a large 
population. 
 
Worth mentioning is that for this thesis, only prescriptions records for the PHC units 
were available. So, our findings are relevant to patients newly treated in the setting of 
CV prevention and naturally, should only be applied to this specific population.  
 
The integration of all prescription records, regardless the health care providing system 
in a single national prescriptions database will allow the escalation of this study and 
others like this to broader populations. Still, this thesis was based on data from a large 
unselected population, which was made possible by the fact that in Portugal, the NHS 
has universal coverage. So, reflect ‘real world’ data. 
 
Despite the limitations, this thesis identified several determinants of adherence to AHT 
therapy in the Lisbon and Tagus Valley Health Region hypertensive patients that can 
provide insight into the development of strategies for early interventions. When 
prescribing AHT drugs, physicians should consider not only the benefits and risks of 
such drugs but also the different characteristics not just of the drug but also of the 
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INTRODUÇÃO  
 
As doenças cardiovasculares (DCV) são, em Portugal, a principal causa de morte, sendo 
responsáveis por 32% do total dos óbitos no País. A hipertensão arterial (HTA) é uma 
doença crónica de elevada prevalência e um fator de risco major para as DCV 
contribuindo, quando não tratada, para a redução da esperança média de vida em 
aproximadamente 5 anos.  
 
Os benefícios da terapêutica anti-hipertensiva (TAH) têm sido extensamente 
demonstrados, através da associação comprovada entre a redução da pressão arterial e a 
redução das complicações cardiovasculares, como sejam enfarte, doença isquémica, 
insuficiência cardíaca ou doença renal.  
 
Não obstante, e apesar da crescente disponibilização no mercado de novos 
medicamentos, com efetividade e tolerância demonstradas, o controlo da HTA 
permanece a níveis inadequados. Em Portugal, estima-se que apenas 42.5% dos doentes 
hipertensos tenham a sua pressão arterial controlada (inferior a 140/90 mmHg).  
 
Diferentes fatores contribuirão para esta realidade, no entanto, um grande (e 
modificável) fator prende-se com o facto de que muitas vezes os doentes não só não 
tomam a medicação como lhes foi prescrita/recomendada (não-adesão) como não a 
tomam de forma contínua/ininterrupta durante longos períodos de tempo (não-
persistência), interrompendo periodicamente ou de forma definitiva o tratamento.    
 
No caso particular da HTA, uma inadequada adesão à TAH e/ou a falha na persistência 
no tratamento contribuem para o desenvolvimento das complicações cardiovasculares 
representando, assim, uma parte importante da mortalidade e morbilidade 
cardiovascular que poderia ser prevenida, tendo um impacto significativo nos outcomes 
clínicos do tratamento da HTA, nas hospitalizações e nos custos associados aos 
cuidados de saúde prestados a estes doentes. 
 
De uma forma geral, a adesão à terapêutica refere-se ao processo pelo qual os doentes 
tomam os medicamentos de acordo com uma dada prescrição/recomendação médica, 
 
166 SUMÁRIO  
integrando três componentes distintas entre si: iniciação, implementação e 
descontinuação.  
 
O processo começa com a iniciação do tratamento, quando o doente toma a primeira 
dose do medicamento prescrito. A partir desse ponto ocorre a implementação do 
tratamento, sendo que nesta etapa o doente toma a medicação tendo em conta uma 
determinada posologia prescrita até à última dose. A descontinuação marca o fim do 
tratamento, não sendo tomadas mais doses posteriormente. O período de tempo entre a 
iniciação e a descontinuação denomina-se persistência.  
 
Deste modo, a não-adesão à terapêutica pode ocorrer numa (ou em mais do que uma) 
das seguintes situações: atraso ou não-iniciação do tratamento, má implementação ou 
interrupção precoce do tratamento prescrito.  
 
A adesão à terapêutica é habitualmente expressa como uma fração ou percentagem das 
doses prescritas e que foram realmente tomadas pelo doente durante um período 
específico de tempo. 
 
A literatura descreve diversos métodos para a realização de estudos de adesão à 
terapêutica, incluindo (i) questionários dirigidos aos doentes / autorrelatos dos doentes; 
(ii) contagem de comprimidos; (iii) utilização de monitores eletrónicos de medicação; 
(iv) utilização de marcadores bioquímicos; (v) taxas de renovação de prescrições, entre 
outros.  
 
A taxa de renovação de prescrições, através da consulta de bases de dados de 
prescrições médicas e/ou de dispensa/faturação das farmácias comunitárias permite o 
estudo da adesão à terapêutica em grandes populações, nas suas três componentes - 
iniciação, implementação e descontinuação - sendo inclusivamente considerado o 
método gold standard para o estudo das componentes de iniciação (nos casos em que é 
possível interligar os registos de prescrição com os registos de faturação) e 
descontinuação (embora a análise seja sempre retrospetiva). 
 
Quando se recorre a bases de dados para o estudo da adesão à terapêutica, 
particularmente no que diz respeito à avaliação da componente da implementação, 
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várias medidas são descritas na literatura, entre as quais o medication possession ratio 
(MPR) e a proportion of days covered (PDC). Com algumas diferenças entre si, ambas 
representam medidas de disponibilidade da medicação prescrita/dispensada durante um 
intervalo de tempo específico. Habitualmente são calculadas dividindo o número de dias 
para os quais a medicação foi prescrita/dispensada durante um determinado período de 
tempo, pelo número de dias que decorreram desde a primeira dispensa até ao final desse 
período. 
 
Já no caso da persistência no tratamento, esta é habitualmente expressa pela definição 
de um período de tempo máximo, para o qual se aceita que o doente esteja sem 
medicação.  
 
Na literatura, a investigação sobre adesão à terapêutica é realizada predominantemente 
com doentes já em tratamento, avaliando a execução/implementação do mesmo. No 
entanto, observam-se valores mais baixos de adesão quando se avaliam novos doentes e 
se consideram não só a implementação do tratamento, como a sua (não) iniciação, uma 
eventual descontinuação precoce do tratamento ou simplesmente a descontinuação 
completa do tratamento ao final de um determinado período de tempo. 
 
Que seja do nosso conhecimento, este é o primeiro estudo de base populacional em 
Portugal que avalia a adesão à terapêutica nas suas três componentes (principalmente 
relevante nas componentes da iniciação e descontinuação), através do recurso a bases de 





Esta tese tem como objetivo geral determinar a adesão à terapêutica anti-hipertensiva, 
nas suas três componentes – iniciação, implementação e descontinuação – em doentes 
que iniciem tratamento da hipertensão arterial nas unidades de cuidados de saúde 
primários da Região de Saúde de Lisboa e Vale do Tejo. Adicionalmente, pretende-se 
identificar fatores de risco para a não-adesão, em cada uma das componentes do 
processo de adesão à terapêutica.  
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MATERIAIS E MÉTODOS 
 
Esta tese corresponde a um estudo observacional, especificamente, um estudo de coorte 
retrospetivo. A coorte foi constituída por todos os doentes com registo de diagnóstico de 
HTA (códigos k86 e k87 da classificação ICPC-2) nas unidades de cuidados de saúde 
primários da região de saúde de Lisboa e Vale do Tejo e a quem, em consequência 
desse diagnóstico, foi prescrita TAH (independentemente do número de medicamentos 
anti-hipertensivos) durante o primeiro trimestre de 2011. 
 
Os medicamentos anti-hipertensivos considerados foram todos aqueles que das 
seguintes categorias (de acordo com a classificação ATC) apresentam explicitamente no 
seu Resumo das Características do Medicamento “hipertensão” como indicação 
terapêutica: C02 – Anti-hipertensores; C03 – Diuréticos; C07 – Agentes 
betabloqueadores; C08 – Bloqueadores dos canais de cálcio e C09 – Agentes que atuam 
no sistema renina-angiotensina.  
 
Os registos de prescrição e de faturação (dispensa mediante a apresentação de uma 
receita médica) foram recolhidos para cada doente, referentes a um período de dois anos 
após a data da primeira aquisição de pelo menos um anti-hipertensivo numa farmácia 
comunitária.  
 
Para uma correta identificação dos novos utilizadores de TAH, para cada elemento da 
coorte foram ainda recolhidos os registos de prescrição e faturação para um período de 
seis meses prévios a 1 de janeiro de 2011 (período de run-in). Deste modo, todos os 
doentes com pelo menos um registo de prescrição e/ou faturação de medicamentos anti-
hipertensivos durante este período foram classificados como utilizadores habituais de 
TAH (por oposição aos novos utilizadores) e dessa forma foram excluído da coorte.  
 
Para além da avaliação das três componentes do processo de adesão à terapêutica, 
avaliamos ainda a adesão primária à TAH, expressa pela relação entre o número de 
registos de faturação sobre o número de registos de prescrição, medida em proporção. 
Nesta análise, a ausência de um registo de faturação para um registo de prescrição de 
um medicamento anti-hipertensivo foi considerada como não-adesão primária.  
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A iniciação da TAH foi definida pela proporção de doentes que adquiriu o primeiro 
medicamento anti-hipertensivo prescrito nos seis meses após a data da primeira 
prescrição. O intervalo de dias entre a primeira prescrição e a primeira aquisição foi 
definido como tempo para iniciação.  
 
 A implementação do regime terapêutico prescrito foi avaliada através da determinação 
do MPR, correspondendo este à relação entre o total de dias para os quais foi 
dispensada medicação e o total de dias em estudo (dois anos): 
 
𝑀𝑃𝑅 =
n.º total de dias para os quais foi dispensada medicação
n.º total de dias em estudo
 x 100 
 
Nos casos em que se verificaram alterações ao regime terapêutico inicial, com a adição 
e/ou a substituição dos medicamentos inicialmente prescritos/dispensados, o 
denominador do MPR foi ajustado. Para os utilizadores de múltiplos medicamentos 
anti-hipertensivos durante o período em estudo, foi determinado o MPR para cada 
medicamento individualmente, correspondendo o MPR por doente, à média dos MPR 
por cada medicamento utilizado por esse doente.  
 
Em função do MPR determinado, os doentes foram inicialmente categorizados em três 
níveis de implementação: baixa (< 40%), intermédia (40-79%) e alta (≥ 80%). Numa 
fase seguinte foram categorizados de forma dicotómica, com base no ponto de corte de 
80%.  
 
A persistência no tratamento corresponde ao intervalo de tempo entre a primeira 
aquisição de um medicamento anti-hipertensivo e o final da embalagem do último 
medicamento adquirido. Para cada um dos elementos da coorte, todos os registos de 
faturação foram analisados consecutivamente e um intervalo de tempo igual ou superior 
a 90 dias entre a duração do último medicamento dispensado e a aquisição do seguinte, 
foi considerado como episódio de descontinuação do tratamento, sendo a data do final 
do último medicamento dispensado definida como a data de descontinuação. Não se 
observando descontinuação do tratamento durante os dois anos do período de 
observação, os doentes foram classificados como persistentes. 
 
170 SUMÁRIO  
 
A reiniciação do tratamento foi também analisada e nesse sentido, apenas foi 
considerada a data do final do último medicamento dispensado, como data de 
descontinuação, independentemente da existência de um ou mais episódios de 
descontinuação durante o período de observação.  
 
Para a análise da implementação e da persistência no tratamento, o número de dias para 
os quais foi dispensada medicação foi definido através de uma posologia padrão diária 
cuja aplicabilidade à prática clínica foi avaliada com recurso a um painel de 30 clínicos.  
 
De forma a identificar os fatores de risco para as várias componentes da adesão à 
terapêutica, recorreu-se à análise de sobrevivência e a modelos de regressão de Cox para 
estimar os hazard ratio (HR) para a iniciação e a descontinuação da TAH e ao um 
modelo de regressão logística para estimar os odds ratio (OR) para níveis baixos de 





Durante o primeiro trimestre de 2011, 29,896 doentes foram diagnosticados com 
hipertensão (códigos k86 e k87, classificação ICPC-2) nas unidades de cuidados de 
saúde primários da Região de Saúde de Lisboa e Vale do Tejo. Após a aplicação dos 
critérios de exclusão, constitui-se uma coorte com 10,204 doentes, 4,645 homens e 
5,559 mulheres com idades compreendidas entre os 18 e os 90 anos, com uma idade 
média de 61.0±13.0 anos e uma mediana de 61.0 anos.  
 
Aproximadamente ¾ (73.9%) dos elementos da coorte residiam na Área Metropolitana 
de Lisboa (AML) no primeiro trimestre de 2011; com base nos códigos das freguesias 
de residência foi possível determinar o poder de compra para cada elemento da coorte, 
tendo-se verificado que cerca de um em cada três elementos residia em municípios com 
baixo poder de compra.  
 
A larga maioria (93.3%) dos doentes foi diagnosticada com ‘hipertensão sem 
complicações’ – código k86 – apesar de diferenças entre o género e a idade dos doentes: 
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a proporção de doentes diagnosticados com ‘hipertensão com complicações’ foi 
superior nos homens e em doentes com idade igual ou superior a 65 anos. 
 
De uma forma geral, das 182,841 embalagens de medicamentos anti-hipertensivos 
prescritas durante o período de observação, 107,024 foram dispensadas numa farmácia 
comunitária, o que corresponde a uma taxa de adesão primária de 58.5%. A adesão 
primária aumentou com a idade dos doentes (p<0.001), foi maior nos homens 
(p=0.020), nos doentes residentes na AML (p<0.001) e para os doentes diagnosticados 
com hipertensão sem complicações (p=0.001).  
 
Não se verificaram diferenças na taxa de adesão primária para os medicamentos 
genéricos comparativamente aos medicamentos de marca (p=0.710), nem quando o 
medicamento foi prescrito pelo médico de família do doente ou por outro especialista 
em medicina geral e familiar (58.9% vs 58.1%; p=0.117).  
 
Analisando a adesão primária em função da classe farmacológica, verificamos que os 
agentes que atuam no sistema renina-angiotensina (C09), particularmente os inibidores 
da enzima de conversão da angiotensina (IECAs) e os antagonistas dos recetores da 
angiotensina II (ARAs) apresentaram as taxas mais elevadas, especialmente para as 
associações fixas (60.2% vs 59.1% para os ARAs e 59.1% vs 57.8% para os IECAs). 
Aumentando o custo para o doente, verificou-se uma diminuição da adesão primária, 
mais relevante para os diuréticos e os betabloqueadores e menos relevante para os 
agentes que atuam no sistema renina-angiotensina.  
 
Do total dos 10,204 elementos da coorte, 493 (4.8%) não adquiriram qualquer 
medicamento anti-hipertensivo durante o período de observação e adicionalmente, 855 
(8.4%) apesar de iniciarem tratamento, fizeram-no com um atraso considerável 
relativamente à data da primeira prescrição (507.2±182.6 dias). Portanto, a taxa de 
iniciação traduziu-se em 86.8%, aumentando com a idade (p<0.001) e diminuindo com 
o poder de compra (p=0.007).  
 
O tempo para iniciação foi inferior nos homens comparativamente às mulheres 
(25.8±27.3 vs 27.0±28.2 dias), aumentando a diferença com o passar do tempo 
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(p=0.024) e para doentes mais jovens (idade inferior a 45 anos) comparativamente com 
os doentes mais velhos (p=0.030).  
 
Tal como para a adesão primária, o facto do(s) primeiro(s) medicamento(s) ter(em) sido 
prescrito(s) pelo médico de família do doente ou por outro clínico, não influenciou a 
decisão de iniciar o tratamento da hipertensão.  
 
Doentes para os quais foram inicialmente prescritos dois ou mais medicamentos (sejam 
em separado ou em associações fixas), apresentaram uma maior taxa de iniciação, 
diminuindo esta, no entanto, com os custos imputados ao doente (88.2% para custos 
<5€ vs 83.6% para custos ≥10€; p<0.001), não se verificando diferenças entre 
medicamentos genéricos e medicamentos de marca (86.1% vs 85.6%; p=0.497).  
 
Tal como para a adesão primária, doentes aos quais foram prescritos IECAs ou ARAs 
(C09) apresentaram as taxas de iniciação mais elevadas, especialmente para as 
associações fixas no caso dos IECAs (87.2% vs 86.0%). 
 
Após ajustamento aos vários potenciais preditores para a iniciação, o modelo de 
regressão de Cox demonstrou que a idade, o género e o medicamento inicialmente 
prescrito (em termos do número de medicamentos prescritos e da classe farmacológica) 
relacionam-se com a iniciação da TAH.  
 
Entre os docentes com uma primeira dispensa de um medicamento anti-hipertensivo 
(n=8,856), 303 (7.5%) homens e 335 (7.0%) mulheres descontinuaram completamente o 
tratamento após a primeira dispensa (embora sem diferenças estatisticamente 
significativas entre os géneros), não adquirindo mais nenhum medicamento durante o 
período de observação, i.e. descontinuação precoce.  
 
A descontinuação precoce foi mais comum nos doentes mais jovens (abaixo dos 45 
anos: 19.7% vs 4.0% nos doentes com idade igual ou superior a 65 anos; p<0.001), nos 
doentes diagnosticados com hipertensão sem complicações (7.2% vs 3.7% para os 
doentes diagnosticados com hipertensão com complicações; p=0.003) e nos residentes 
na região do Médio Tejo. Não se verificou associação entre o poder de compra e a 
descontinuação precoce da TAH.  
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Analisando o efeito da classe farmacológica utilizada inicialmente na decisão de 
descontinuar de forma prematura o tratamento, os nossos dados indicam que os doentes 
que iniciaram o tratamento com um betabloqueador ou um diurético apresentaram uma 
maior taxa de descontinuação precoce do que os doentes que iniciaram tratamento com 
um IECA ou um ARA. Estas diferenças foram estatisticamente significativas (p<0.001). 
 
Também à semelhança das análises anteriores, o uso de associações fixas, bem como o 
custo por embalagem inferior a 5€ tiveram impacto positivo na decisão de prolongar o 
tratamento pelo menos para além da primeira embalagem prescrita/adquirida. Não se 
verificaram diferenças estatisticamente significativas entre os doentes que iniciaram 
tratamento com um medicamento genérico comparativamente aos que iniciaram 
tratamento com um medicamento de marca (8.7% vs 8.4%; p=0.569).  
 
Durante o primeiro ano de tratamento, 21.6% dos homens e 23.1% das mulheres não 
tiveram qualquer episódio de descontinuação da TAH, reduzindo, no entanto, esses 
valores para 5.8% nos homens e 6.3% nas mulheres, no final do segundo ano de 
tratamento. As diferenças entre os géneros foram estatisticamente significativas 
(p=0.037), apresentando as mulheres uma maior persistência.  
 
A persistência diminuiu de forma clara com a idade: apenas 1.8% (16) dos doentes com 
idade inferior a 45 anos não teve qualquer episódio de descontinuação do tratamento vs 
8.2% dos doentes com idade igual ou superior a 65 anos. A persistência também se 
revelou menor no escalão mais elevado do poder de compra (4.4% vs 6.0%; p=0.034) e 
para os doentes diagnosticados com hipertensão sem complicações (5.8% vs 9.4%; 
p=0.001). 
 
Doentes que iniciaram tratamento com um diurético em formulação simples 
apresentaram a menor persistência (3.8%) para todas as classes farmacológicas, ao 
passo que o valor mais elevado se verificou para os doentes que iniciaram tratamento 
com uma associação fixa de dois diuréticos (7.7%). No entanto, é importante referir que 
esta análise apenas teve em consideração o(s) medicamento(s) utilizado(s) no início do 
tratamento, independentemente do(s) mesmo(s) ser(em) 
substituído(s)/complementado(s) durante o período de observação.   
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Após ajustamento aos vários potenciais preditores para a descontinuação (não-
persistência), o modelo de regressão de Cox demonstrou que a idade, o número de 
medicamentos dispensados por doente durante o período de observação e o número de 
prescritores para o mesmo doente relacionam-se com a descontinuação da TAH.  
 
Quando se tem em consideração a reiniciação do tratamento e se ajusta a definição de 
persistência em função dessa reiniciação, a persistência aumenta consideravelmente, 
verificando-se que a larga maioria dos doentes reiniciam o tratamento após um episódio 
de descontinuação durante o período de observação e dessa forma, no final do segundo 
ano, 72.2% ainda se encontram em tratamento com pelo menos um medicamento anti-
hipertensivo, com uma maior proporção de mulheres (73.6% vs 70.6%; p=0.002) e de 
doentes com idade igual ou superior a 65 anos (79.4% vs 48.5% de doentes com igual 
inferior a 45 anos).  
 
Os doentes residentes no Médio Tejo apresentaram uma maior descontinuação (mesmo 
tendo em consideração uma possível reiniciação do tratamento), tal como os doentes 
diagnosticados com hipertensão sem complicações (26.2% vs 21.1%; p=0.012).  
 
Analisando a persistência (incluindo a reiniciação) em função da classe farmacológica, 
verifica-se que doentes que iniciaram tratamento com um diurético (isolado ou em 
associação fixa) ou um betabloqueador apresentarem menor persistência. Doentes que 
iniciaram tratamento com uma associação fixa de um ARA ou um IECA com um BEC 
ou um diurético apresentaram maior persistência comparativamente às formulações 
isoladas desses medicamentos (73.0% vs 69.7% para os IECAs e 73.3% vs 72.0% para 
os ARAs).  
 
Após ajustamento aos vários potenciais preditores para a descontinuação, não 
considerando períodos os episódios de descontinuação, o modelo de regressão de Cox 
demonstrou que a idade, o número de medicamentos dispensados por doente durante o 
período de observação, o número de prescritores para o mesmo doente, o poder de 
compra e a classe farmacológica inicialmente prescrita relacionam-se com a 
descontinuação da TAH.  
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Por fim, analisando a implementação do tratamento ao longo dos dois anos de 
observação, apenas 456 (5.1%) doentes tiveram medicação disponível para 80% ou 
mais dos dias de tratamento, principalmente os homens (5.4% vs 4.9% das mulheres), 
embora esta diferença não tenha sido estatisticamente significativa. Em média, os 
doentes tiveram medicação para 43.6±23.1% (em dias) dos dois anos do período de 
observação (mediana: 44.0%).  
 
Níveis mais elevados de implementação foram também encontrados nos doentes com 
idade igual ou superior a 65 anos, e para as restantes variáveis de caracterização dos 
doentes não se encontraram quaisquer diferenças com significado estatístico. No 
entanto, verificou-se uma tendência para níveis mais elevados de implementação nos 
doentes com menor poder de compra. 
 
Tal como nas análises anteriores, também na implementação do regime terapêutico, os 
níveis mais baixos foram encontrados para os diuréticos (42.3% nas associações fixas) e 
os níveis mais elevados para as associações fixas de IECAs e ARAs com outros anti-
hipertensivos.  
 
O modelo de regressão logística demonstrou que a idade, o número de medicamentos 
dispensados por doente durante o período de observação, o número de prescritores para 
o mesmo doente, e o poder de compra relacionam-se com níveis mais baixos de 
implementação da TAH. No entanto, e contrariamente ao que se verificou para a 
persistência, um maior número de medicamentos dispensados por doente diminui a 
qualidade da implementação.  
 
DISCUSSÃO E CONCLUSÕES 
 
Os resultados desta tese confirmam observações anteriores de que na prática clínica, o 
tratamento da hipertensão é frequentemente abandonado e implementado de forma 
deficitária ao longo do tempo.  
 
Praticamente um em cada cinco (19.5%) doentes ou não inicia tratamento, ou fá-lo com 
um atraso considerável (em média, praticamente um ano e meio depois de ter recebido 
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uma primeira prescrição) ou descontinua completamente o tratamento logo após a 
primeira dispensa. 
 
O risco de descontinuação é mais acentuado durante o primeiro ano de tratamento, 
principalmente para os doentes mais jovens. Diferentes fatores poderão contribuir para 
esta maior descontinuação nos mais jovens. Desde logo, a natureza assintomática da 
HTA, que associada a eventuais efeitos secundários da própria TAH poderão contribuir 
para uma menor perceção da necessidade de realizar tratamento. Por outro lado, o 
tratamento da HTA não depende apenas da prescrição de medicamentos. A modificação 
dos estilos de vida poderá ter impacto positivo na evolução da doença, particularmente 
nos doentes mais jovens, com provavelmente menos fatores de risco cardiovasculares. 
Nesse sentido, importa avaliar em estudos futuros o impacto da modificação dos estilos 
de vida no controlo da pressão arterial e, dessa forma, a sua relação com a adesão à 
TAH.  
 
Um achado particularmente relevante nesta tese é a de que a larga maioria dos doentes 
utiliza a TAH de forma descontinuada, interrompendo-a e reiniciando-a de forma 
frequente. Isto implica que a decisão de descontinuar tratamento não é uma decisão 
definitiva. No entanto, é particularmente preocupante no caso de um doente que 
efetivamente necessita de tratamento, não realizá-lo durante períodos longos e 
consecutivos. Nesse sentido, os prescritores deverão de forma ativa tentar monitorizar a 
utilização da TAH por parte dos doentes, de forma a proactivamente tentar identificar 
possíveis limitações à utilização dos medicamentos prescritos.  
 
Na prática clínica é relativamente comum que, na ausência de controlo de determinada 
doença, o prescritor responda aumentando as doses dos medicamentos prescritos ou até 
mesmo modificando ou acrescentando novos medicamentos. No entanto, a falta de 
controlo de determinada doença é, muitas vezes, o resultado da falta de adesão à 
terapêutica e não da falta de efetividade do tratamento. Portanto, na falta de efetividade 
de um tratamento, o prescritor deve colocar a questão: será que o medicamento falhou 
na sua atividade ou será que o doente falhou a sua utilização? 
 
Se praticamente um em cada dois medicamentos prescritos não são dispensados numa 
farmácia (taxa de não-adesão primária = 41.5%), o que se reflete num MPR médio de 
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43.6±23.1%, então os potenciais benefícios da TAH não serão completamente 
realizados, diminuindo a proteção contra as complicações da hipertensão não controlada 
e aumentando o risco cardiovascular nestes doentes.  
 
A baixa adesão à TAH encontrada nesta tese – em todas as suas componentes – é 
particularmente preocupante, já que esta condição contribui grandemente para o peso da 
morbilidade e mortalidade das DCV em Portugal.  
 
Até à realização desta tese, a adesão à TAH tinha sido avaliada, em Portugal, quase 
exclusivamente na componente da implementação. A adesão à terapêutica é um 
processo dinâmico, influenciado por múltiplos fatores em diferentes momentos 
temporais e como tal, a sua avaliação transversal e descrição num único número ou taxa 
ou percentagem, corresponde a uma simplificação de uma realidade complexa, com 
pouco impacto na definição de programas de intervenção nos padrões de utilização dos 
tratamentos. Os fatores que influenciam a decisão de iniciar um tratamento não são 
necessariamente os mesmos que determinam a sua (eventual) descontinuação, tal como 
foi demonstrado nesta tese.  
 
A avaliação da adesão à terapêutica é fundamental para uma melhor compreensão dos 
fatores relacionados com a não-adesão, para habilitar, de forma eficiente, a identificação 
de medidas que visem a sua melhoria e, consequentemente, a melhoria dos resultados 
em saúde, uma vez que a adesão relaciona-se com os outcomes clínicos e os custos com 
os cuidados de saúde prestados a estes doentes. 
 
O relatório da Organização Mundial da Saúde sobre adesão à terapêutica nas doenças 
crónicas faz eco da sugestão de Haynes et al., de que aumentar a efetividade das 
medidas que promovam uma maior adesão à terapêutica poderá ter um maior impacto 
nos cuidados de saúde – a nível terapêutico mas também a nível económico – que 
qualquer melhoria no tratamento médico propriamente dito.  
 
Nesse pressuposto, os benefícios da utilização das bases de dados de prescrições 
médicas e dispensa/faturação das farmácias comunitárias devem ser considerados não só 
na avaliação da adesão à terapêutica mas também na monitorização da efetividade das 
medidas que visem a promoção de adesão.  
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Embora o estudo da adesão à terapêutica com recurso a bases de dados eletrónicas 
apresente algumas limitações, como, por exemplo, a incapacidade de garantir que o 
doente efetivamente tomou o medicamento levantado na farmácia, as grandes bases de 
dados revelam-se particularmente úteis na avaliação da adesão às classes terapêuticas 
indicadas para os tratamentos crónicos. Quando não exista a possibilidade de adquirir os 
medicamentos a partir de outras fontes não capturadas na base de dados, a 
especificidade desta metodologia para detetar os doentes que não tomam os 
medicamentos prescritos é, efetivamente, muito alta 
 
Num momento em que a prescrição eletrónica de medicamentos é obrigatória em 
Portugal e o processo de conferência das receitas médicas se encontra centralizado num 
centro de conferências de faturas nacional, esta deverá ser nos próximos tempos, uma 
das principais fontes de informação na investigação da adesão à terapêutica.  
 
